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CHAPTER I 
 
INTRODUCTION 
 
Overview 
Head and Neck Squamous Cell Carcinoma (HNSCC) accounts for more than 90% of all head and 
neck cancers and is the sixth most common cancer worldwide with approximately 50,000 cases 
occurring annually in the United States. Exploring molecular contributors to HNSCC, we have 
previously reported that expression of LZAP is lost in about 30% of HNSCC. LZAP (also called 
CDK5rap3 or C53) was first described as a binding partner of the 35kDa CDK5 activator binding 
protein p35
Nck5a
 in 2000 (Ching et al., 2000). Activity of CDK5rap3 in association with p35
Nck5a
 
has not been further characterized and is not likely to represent its major activity since expression 
of CDK5 and p35
Nck5a
 is restricted to neurons while LZAP is ubiquitously but variably expressed 
in all tissues we tested (Ching et al., 2000; Wang et al., 2006). Consistent with alternative roles 
for CDK5rap3, we have identified this protein as a novel binding partner for the tumor suppressor 
ARF (alternative reading frame) through an unbiased yeast two-hybrid screen approach in 2006. 
Based on these data, we renamed this protein LZAP for LXXLL/leucine zipper-containing ARF-
binding protein. LZAP is a highly conserved protein in vertebrates, invertebrates and plants, but 
homologues do not exist in yeast and bacteria. Inside the cell, LZAP localizes to cytoplasmic and 
nuclear compartments. Database search and literature to date to identify homologs and conserved 
domains revealed that LZAP shares no significant amino acid homology with any other known 
proteins and has no conserved functional domains, except for putative leucine zipper (amino acid 
357-385) and LXXLL motifs. However, we previously demonstrated that LZAP loss promotes 
tumor growth in vivo and that LZAP is lost in ~30% of human HNSCC (Wang et al., 2007a). We 
have targeted LZAP in mice and our preliminary findings suggest that mice with targeted LZAP 
are susceptible to lung tumor formation (unpublished data). Collectively, these data suggest that 
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LZAP functions as a tumor suppressor. Molecular mechanisms of LZAP activities continue to 
emerge. We and others have described LZAP functions to regulate activities of ARF, p53, p38 
MAPK, NF-κB, Wip1, Chk1 and Chk2. 
 
Mechanisms of LZAP activity 
LZAP and ARF 
The tumor suppressor ARF is a product of the INK4a/ARF locus, which encodes p16
INK4a
 and 
p14
ARF
 (p19
ARF
 in mice), two unrelated tumor suppressors (Quelle et al., 1995). While p16
INK4a
 
prevents phosphorylation of the Rb (retinoblastoma protein), which is important for its growth 
suppressive functions, the activity of ARF is linked to its interaction and inhibition of MDM2 
(HDM2 in human), the major negative regulator of the human tumor suppressor p53 (Pomerantz 
et al., 1998; Zhang et al., 1998). ARF expression can be induced by multiple oncogenic stimuli, 
resulting in a p53-dependent cell cycle arrest and/or apoptosis (Weber, 2000). As such, ARF 
functions as a major cellular defense protecting the cells with excessive proliferative signaling 
and consequently, many human tumor types are detected with loss of ARF expression. ARF has 
been shown to counteract the p53-inhibitor functions of MDM2 and at least two models have 
been proposed (Weber et al., 1999; Zhang and Xiong, 1999). First, ARF disrupts HDM2 binding 
to p53 and sequesters HDM2 in the nucleolus (Tao and Levine, 1999). Second, ARF binds and 
forms a ternary complex with HDM2 and p53 in the nucleus, and inhibits HDM2’s ubiquitination 
and transcriptional inhibition of p53 (Zhang and Xiong, 2001). 
 
In addition to the p53-dependent activities of ARF, emerging data suggests that ARF may be 
involved in cellular processes independent of p53, including cell cycle arrest, ribosomal 
biogenesis and apoptosis (Donehower et al., 1992; Kamijo et al., 1999). If all tumor suppressive 
functions of ARF were attributed solely to functional p53, the tumor phenotypes of p53
-/-
 mice 
would be more severe and encompass the ARF
-/-
 tumorigenesis phenotype. However, distinct 
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differences are observed during tumor formation in ARF
-/-
 mice compared to p53
-/-
 mice 
(Donehower et al., 1992; Kamijo et al., 1999). For example, a substantial percentage of ARF
-/-
 
mice spontaneously develop carcinomas and neurogenic tumors which are rarely observed in p53
-
/-
 mice, and therefore might be p53 unrelated. Additional supporting evidence came from 
oncogene-induced lymphoma in p53/ARF double KO mice, which develop tumors earlier and are 
more resistant to therapy compared to lymphoma derived from either p53 or ARF single KO mice 
(Schmitt et al., 1999). These data suggest that loss of p53 and ARF may have similar, but not 
identical effects on tumor formation. The mechanisms by which ARF enhances tumor formation 
independent of p53 are not well known, thus studying the regulators of ARF is of great 
importance for a full spectrum of ARF tumor suppressive functions. 
 
It has been reported and well characterized that regulation of ARF transcription can by activated 
by inappropriate hyperproliferative oncogenic signaling, such as that provided by E1A, ras, myc 
and E2F-1 (Bates et al., 1998; Palmero et al., 1998; Zindy et al., 1998; de Stanchina et al., 1998). 
However, more recent studies suggest that ARF can also be regulated post-translationally. The 
ARF tumor suppressor is subject to proteasome-mediated degradation after N-terminal 
polyubiquitination (Kuo et al., 2004). Furthermore, the nucleolar protein nucleophosmin (NPM) 
sequesters ARF in the nucleolus, by competitive binding with HDM2 through the same domain, 
thus impairing ARF-mediated p53 stabilization and activity (Korgaonkar et al., 2005). Several 
other ARF-binding partners have been identified, such as E2F-1, HIF-1α and a novel protein, 
CARF (Eymin et al., 2001; Fatyol and Szalay, 2001; Hasan et al., 2002). Most of these binding 
partners do not regulate ARF activity toward p53, either positively or negatively (Vivo et al., 
2001; Hasan et al., 2002). To identify ARF-interacting proteins that may be involved in the 
regulation of ARF activity, we used a yeast two-hybrid system and screened for binding partners. 
LZAP was a novel human protein that bound ARF and was identified from the screen. Binding of 
LZAP to ARF was confirmed in mammalian cells both in vitro and in vivo. The identified protein 
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proved to be highly similar to the rat protein C53, which was previously identified as a p35-
associated protein, the precursor of the CDK5 activating subunit (Ching et al., 2000). Our lab has 
previously shown that this leucine Zipper-containing ARF-binding Protein (LZAP) directly and 
specifically binds to the N-terminal region of human ARF, and that this interaction is induced by 
oncogenic stimulation. Upon direct binding to ARF, LZAP reverses ARF inhibition of HDM2’s 
p53 ubiquitination activity, but despite of its ability to restore HDM2-mediated p53 ubiquitination 
in the presence of ARF, LZAP does not decrease p53 stability. Surprisingly, LZAP results in 
further augmentation of p53 transcriptional activity. Ectopic expression of LZAP plasmids in 
mammalian cells induces p53-dependent G1 cell cycle arrest. But a similar pattern of p53 
activation is observed in ARF null cells. These findings suggest that LZAP regulates p53 through 
unknown ARF-independent mechanism(s) that are independent of ARF. 
 
LZAP and the p53 pathway 
The tumor suppressor protein 53, is one of the two major tumor suppressors implicated in human 
cancers (Weinberg, 1995) and is frequently mutated in HNSCC. Major tumor suppressor 
activities of p53 include induction of apoptosis and inhibition of cellular proliferation mediated 
through p53’s transcriptional activity and by a mitochondria pathway. Because p53 regulates 
cellular proliferation and apoptosis, p53 activity within the cell is tightly controlled at multiple 
levels. 
 
Mutations that alter p53 activity occur in approximately 50% of human cancers, including 
HNSCC, and have been associated with poor overall survival in HNSCC (Soussi et al., 2006; 
Poeta et al., 2007). Excluding mutations or loss of expression, the molecular pathways 
responsible for inhibition of p53 activity in cancer remain to be fully elucidated; however, themes 
observed in many cancers impact p53 protein modification and/or p53 protein stability (Ko and 
Prives, 1996). Both the human papilloma virus (HPV) E6 protein and the endogenous HDM2 
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protein are oncogenes that serve as p53 ubiquitin ligases and play a critical role in targeting p53 
for degradation (Scheffner et al., 1993; Kubbutat et al., 1997). Most tumors with amplified or 
overexpressed HDM2 or with HPV E6 expression do not acquire p53 mutations and maintain 
expression of wild-type p53 suggesting that inactivation of p53 by E6 or HDM2 sufficiently 
inhibits p53 to support tumorigenesis (Leach et al., 1993; Braakhuis et al., 2004). HDM2 is the 
major cellular regulator of p53 stability acting as a p53 E3 ubiquitin ligase resulting in p53 
degradation that is dependent on the 26S proteasome (Lavin and Gueven, 2006). Because of its 
central role in regulation of p53, HDM2 activity is also regulated at multiple levels. As part of a 
negative feedback loop, p53 increases HDM2 transcription, and post-transcriptional modification 
of p53 and HDM2 modulate the ability of HDM2 to bind p53. ARF is the major protein inhibitor 
of HDM2 activity and is thought to primarily protect against inappropriate mitogenic stimulation 
and therefore tumorigenesis (Zindy et al., 2003; Views, 2004). ARF binds HDM2 and inhibits its 
p53 E3 ubiquitin ligase activity while simultaneously reversing HDM2’s inhibition of p53 
transactivation (Zhang et al., 1998; Zhang and Xiong, 2001). ARF expression is induced by 
multiple oncogenic stimuli resulting in p53-dependent cell cycle arrest and/or apoptosis (Sherr, 
1998; Sherr and Weber, 2000). In this capacity, ARF directs a major cellular defense protecting 
the organism from cells with excessive proliferative signaling, and as a result, many human tumor 
types, including HNSCC, have frequent loss of ARF expression. 
 
Although p53 protein stability is largely controlled by HDM2, it is also tightly controlled through 
a myriad of post-translational modifications including ubiquitination, phosphorylation, 
acetylation and sumoylation. As opposed to the p53 inhibitory role of ubiquitination, 
phosphorylation stabilizes and activates p53 (Lavin and Gueven, 2006). Phosphorylation of 
p53occurs by at least 19 kinases targeting 17 distinct serine or threonine residues (Dai and Gu, 
2010). Phosphorylation of most residues of p53 results in stabilization, nuclear accumulation, and 
increased transcriptional activity. p53 phosphorylation is concentrated at the N-terminus of the 
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protein, which is responsible for transactivation and binding to HDM2, and at the C-terminal 
regulatory domain. Phosphorylation of Ser15 (Ser18 in mice) is the most commonly described 
modification of p53 and may serve as an initiator that potentiates further phosphorylation at 
Thr18 and Ser20 (Lavin and Gueven, 2006). Ser15, Thr18, and Ser20 are key residues for 
activation of p53 in response to DNA damage or cellular stress triggering recruitment of acetyl 
transferases, inhibition of MDM2 binding, and stabilization of p53. These residues in the N-
terminus of p53 are phosphorylated by the DNA damage response proteins ATM/ATR, by the 
stress activated protein kinase p38 MAPK, and by DNA damage-associated checkpoint kinases 
Chk1/2 (Lavin and Gueven, 2006; Dai and Gu, 2010). 
 
We have shown that LZAP further activates p53 in the presence of ARF (Wang et al., 2006). 
LZAP binds ARF, co-localizes with ARF, and forms a ternary complex with ARF, HDM2 and 
p53. Expression of LZAP in the presence of ARF further enhances p53-mediated expression of 
the cyclin-dependent kinase inhibitor p21
Cip1
 and enhances the ARF-mediated G1 cell cycle arrest.  
Mechanistically LZAP was found to stabilize p53 protein in the presence of HDM2 through 
inhibition of p53 nuclear export (Wang et al., 2006). Remarkably, we also found that in the 
absence of ARF, LZAP increases p53 transcriptional activity with resultant G1 cell cycle arrest. 
Because LZAP does not inhibit proliferation in cells lacking p53 activity , LZAP mediated cell 
cycle arrest is dependent on p53 (Wang et al., 2006). These data reveal that LZAP activates p53 
in the presence and absence of ARF. The mechanism of LZAP activity in the absence of ARF 
was previously not described, but could be explained by novel LZAP-binding partners (see 
preliminary data). 
 
LZAP and the NF-κB pathway 
Nuclear factor-kappa B (NF-κB) was discovered in the mid-1980s as a sequence-specific DNA-
binding protein that recognizes a DNA element in the mouse immunoglobulin (Ig) κ gene intronic 
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enhancer (Sen and Baltimore, 1986). It has been the focus of intense investigation since its 
discovery, chiefly because of the pleiotropic effects and vital roles in immunity, inflammation, 
stress response and tumorigenesis. Aberrant regulation of NF-κB signaling pathways is 
implicated in a wide range of human diseases, such as cancer, AIDS (Acquired Immune 
Deficiency Syndrome), diabetes, and viral infections (Kumar et al., 2004). 
 
In mammals, there are five NF-κB/REL genes that encode seven proteins: RelA, cRel, RelB, NF-
κB1 (also known as p50/p105) and NF-κB2 (also known as p52/100) (Fig. 1.1). All members of 
the family share a conserved sequence motif, the Rel homology domain (RHD) that spans nearly 
300 amino acids and is responsible for homo/heterodimerization, DNA-binding and nuclear 
localization. Post translational modifications of amino acids within the RHD alter both DNA 
binding and transactivation properties of NF-κB. Only RelA, c-Rel and RelB contain 
transactivation domains (TAD) necessitating their presence within transcriptionally active NF-κB, 
while the other two family members, p50 and p52 lack TAD and functioning primarily as DNA-
binding subunits in the complex. Among various NF-κB homo/heterodimers, the ubiquitously 
expressed RelA/p50 heterodimer is the most abundant form, and is responsible for most NF-κB 
function in different cell types, thus this heterodimer is often referred as NF-κB in general. Figure 
1.1 is a schematic representation of Rel family members, as well as IκB family members that 
primarily function in NF-κB regulation. 
 
The role of NF-κB as a tumor promoter/oncogene in the development of cancer was suspected 
because v-Rel, the viral homologue of c-Rel, causes aggressive tumors in chickens (Gilmore, 
1999). It later became obvious that NF-κB, or more precisely the RelA/p50 heterodimer which 
comprises the most studied form of NF-κB, is activated in various tumor types and that activation 
of NF-κB promotes many aspects of oncogenesis including anchorage independent growth, 
angiogenesis, and proliferation while protecting tumor cells from apoptosis (Rayet and Ge, 1999;  
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Figure 1.1. Members of the NF-κB and IκB Protein Families 
NF-κB family is characterized by having the Rel homology region (RHR) shown in green and 
yellow. IκB proteins are characterized by the presence of ankyrin repeat domain (ARD) 
shown in blue. 
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Baldwin, 2001). NF-κB activation has been described in head and neck squamous cell carcinoma 
(HNSCC) with aberrant regulation of multiple NF-κB responsive genes identified by gene 
expression profiling of these cancers (Dong et al., 2001). The regulation of many genes that is 
controlled by NF-κB includes those involved in development, inflammation, immune response, 
proliferation, apoptosis, cellular transformation, angiogenesis and differentiation (Orlowski and 
Baldwin, 2002). The realization that NF-κB inhibits cellular apoptosis in response to cytokines 
led to investigation regarding its role in resistance to chemotherapy. Exposure of cancer cells to 
IR and chemotherapeutic agents was found to activate NF-κB. Inhibition of NF-κB, using a 
stabilized and mutated IκBα, termed IκB-super repressor (IκB-SR), remarkably increases the 
apoptotic response to these same cytotoxic agents (Baldwin, 2001). Recently, inhibition of NF-κB 
has evolved as a novel therapeutic target for cancer treatment. Using HNSCC cell lines, inhibition 
of NF-κB was found to increase cell sensitivity to radiation resulting in increased cell death (Kato 
et al., 2000). This enhanced chemo/radiotherapy-induced apoptosis in the presence of NF-κB 
inhibition is p53 independent (Baldwin, 2001). These data suggest that NF-κB activity may 
protect cancer cells from many of the commonly used therapeutic agents.  
 
NF-κB activity is maintained under basal levels in unstressed cells, primarily through the 
inactivation by IκB proteins. IκB binds to the RHD and masks the nuclear localization signals 
(NLS) of NF-κB. In response to many different intracellular or extracellular signals such as TNFα 
and IL-1, the upstream IκB kinases (IKKα/β/γ) phosphorylate IκB and target it for ubiquitination 
and degradation dependent on the 26S proteasome. This degradation of IκB results in nuclear 
translocation of NF-κB. Like many other transcriptional factors such as p53, the DNA binding 
and transcriptional activities of NF-κB is regulated by multiple post-translational modifications to 
RelA, such as acetylation and phosphorylation (Gu and Roeder, 1997). Three types of distinct 
NF-κB activation signaling pathways have been described that have been called as the 
―canonical‖, ―non-canonical or alternative‖ and ―atypical‖ pathways. The canonical pathway is 
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well characterized by TNFα induced NF-κB activation. Upon TNFα stimulation, IKKβ/γ complex 
is activated and then phosphorylates IκBα, which promotes its recognition by an E3 ubiquitin 
ligase resulting in proteasome-mediated degradation. However, the alternative pathway is 
preferentially activated by a subset of other cytokines such as lymphotoxin β (LTβ), induce NF-
κB activation through a different mechanism, primarily through IKKα activity resulting in 
RelB/p52 phosphorylation and processing to produce its active form, the RelB/p52 heterodimer. 
The resultant complex translocates into nucleus and initiates transcription of various target genes. 
Both pathways described above converge to activate the IKK complex and are dependent on its 
kinase activity. The more recently described ―atypical‖ pathway suggests that some stresses, such 
as DNA damage induced by IR or doxorubicin, activate NF-κB independent of the upstream IKK 
kinases (Tergaonkar et al., 2003). For example, doxorubicin-induced degradation of IκB does not 
require phosphorylation of IκB, and thus is independent of IKKα/β activity (Tergaonkar et al., 
2003). Although NF-κB is one of the most intensively studied transcription factors, and multiple 
regulatory pathways have been well illustrated, many facets of the delicate regulation of NF-κB 
remain unexplored. Novel mechanisms that regulate NF-κB activity are likely to be important in 
tumorigenesis and/or response of tumors to therapy. 
 
We have shown that LZAP expression markedly inhibits RelA activity even in the presence of the 
NF-κB stimulating cytokines, TNFα and IL-1, or RelA overexpression. In fact, LZAP is as 
effective at inhibiting RelA transcription as IκB-SR. Conversely, loss of LZAP increases both 
basal and cytokine-induced RelA transcriptional activity. Functionally, decreased expression of 
LZAP increases expression of MMP-9 and increases cellular invasion, both dependent on NF-κB 
(Wang et al., 2007a). These data suggest that LZAP is a potent NF-κB inhibitor and that 
endogenous LZAP inhibits both basal and activated NF-κB. 
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Mechanistically, LZAP does not alter RelA DNA binding or nuclear localization suggesting that 
LZAP inhibition of RelA is mediated by physical interaction with or post-translational 
modification of RelA. We showed that LZAP binds RelA and that LZAP is found on chromatin at 
RelA promoters (MCP-1 and IL-8), and that LZAP loss in primary HNSCC is associated with 
increased IL-8 expression in the tumor (Wang et al., 2007a). LZAP expression is associated with 
decreased phosphorylation at S536 of RelA, and conversely, inhibition of LZAP expression 
increases phosphorylation at this same critical site. LZAP expression is also associated with 
increased histone deacetylases (HDACs) binding to RelA and with deacetylation of histones at 
RelA responsive promoters (MCP-1, IL-8). Collectively, these data suggest that LZAP regulation 
of NF-κB activity requires LZAP association with RelA and modification of RelA 
phosphorylation status. 
 
LZAP and Chk1/2 
To date, there is a single publication describing LZAP activity towards the checkpoint kinases 
Chk1 and Chk2 (hereafter called Chk1/2) (Jiang et al., 2009). Passage through the G2/M 
checkpoint depends on activation of the CDK1/cyclin B complex and is tightly regulated by 
Chk1/2 through CDC25. Recent evidence indicates that in response to DNA damage, additional 
pathways also impact the G2/M checkpoint through regulation of CDC25, such as the p38 kinases 
(Bulavin et al., 2002a). Endogenous and exogenous stresses, such as replication fork collapse or 
IR, result in DNA damage and activation of the apical serine/threonine protein kinases belonging 
to the PIKK family, including ATM, ATR and DNA-PK. Activated PIKKs in turn phosphorylate 
and activate the downstream checkpoint kinases Chk1/2. Although both Chk1 and Chk2 can 
phosphorylate and inhibit CDC25, Chk1 seems to be the primary kinase responsible for the G2/M 
checkpoint (Graves et al., 2000). Chk1/2-mediated phosphorylation of CDC25C at S216 is 
required for its recruitment of 14-3-3. Binding of 14-3-3 to CDC25C, either directly or through 
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cytoplasmic sequestration, inhibits CDC25C binding to the CDK1/cyclin B complexes (Bulavin 
et al., 2002a). 
 
Jiang et. al. reported that during DNA damage response, LZAP inhibits Chk1/2 phosphorylation 
and activation. By counteracting Chk1, LZAP activates CDC25C resulting in downstream CDK1 
activation (Jiang et al., 2009) (Fig. 1.2). It is well known that Chk1/2 are phosphorylated and 
activated after DNA damage by ATM and ATR. Expression of LZAP is associated with 
decreased phosphorylation and inhibition of Chk1/2, but this effect is not mediated through 
decreasing the activities of their upstream kinases. Since checkpoint kinases are inhibited by 
LZAP, their activity toward CDC25C is similarly inhibited, resulting in activation of CDK1 and 
inappropriate or early progression into mitosis (Jiang et al., 2009). Conversely, Jiang et. al. have 
shown that knockdown of LZAP inhibits of CDK1 and delays mitotic entry (Jiang et al., 2009). 
These results are consistent with an earlier report by the same group that LZAP increases 
sensitivity to genotoxins related to inappropriate progression through the G2/M checkpoint (Jiang 
et al., 2005). These data show that LZAP binds and inhibits Chk1 resulting in dysregulation of 
cell cycle progression, but Chk1 and Chk2 kinases phosphorylate and regulate targets in addition 
to CDK1, including p53. Mechanistically, it remains unclear how LZAP alters Chk1/2 
phosphorylation and activity. 
 
LZAP and p38 MAPK 
The p38 mitogen-activated protein kinase (MAPK) family (p38α/β/γ/δ) together with the c-Jun N-
terminal kinase (JNK) family belong to the stress-activated protein kinases (SAPKs) that 
primarily respond to cellular stress (osmotic, heat shock, DNA damage etc.) and/or cytokines 
(Waskiewicz and Cooper, 1995; Bulavin and Fornace, 2004). Both p38α and p38β are 
ubiquitously expressed, but expression patterns suggest that p38α is more abundant in most cell 
types, including HNSCC cell lines, and p38α has been most extensively studied (Junttila et al.,  
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Figure 1.2. LZAP Inhibits Checkpoint Kinases 
LZAP inhibits Chk1 and Chk2 causing activation of CDC25C and CDK1. Simplified, LZAP 
is an activator of CDK1 through inhibition of checkpoint kinases. Arrows indicate activation 
and T shapes indicate inhibition. 
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2007; Wagner and Nebreda, 2009). The other three isoforms, p38β/γ/δ, have more restricted 
patterns of expression and have relatively low expression levels. 
 
p38 is activated by many extracellular stimuli through a classic MAPK kinase kinase (MAP3K)-
MAPK kinase (MKK) signaling pathway. The major upstream activating kinases that are 
responsible for activation of p38 are MKK3 and MKK6, although other mechanisms such as 
MKK4 and auto-phosphorylation may also contribute to p38 activation (Cuenda and Rousseau, 
2007). p38 activity regulates a wide range of substrates including transcription factors, such as 
p53, activating transcription factor 2 (ATF2) and NF-κB (Raingeaud et al., 1996; Bulavin et al., 
1999; Saccani et al., 2002). Interestingly, the pleiotropic biologic effects of p38 activity have 
suggested that p38 can function both as a tumor suppressor and a tumor promoter. 
 
Studies have focused on p38 tumor suppressor-like activities, mediated through cell cycle arrest, 
senescence, and apoptosis in many different cell types (Bulavin and Fornace, 2004). p38 engages 
multiple genes and pathways to regulate cell cycle arrest at both the G1/S and G2/M checkpoint 
(Bulavin and Fornace, 2004; Wagner and Nebreda, 2009). p38-mediated degradation of the G1 
cyclin D1 contributes to G1 arrest (Thoms et al., 2007). p53 is also a direct substrate of p38 
kinase activity, which can be phosphorylated by p38 on Ser33 and Ser46, inducing transcription 
of the p21
Cip1
, with resultant inhibition of both G1 and G2 CDKs (Bulavin and Fornace, 2004). In 
addition to cell cycle inhibition through increasing p21 expression, p38 directly inhibits G2/M 
progression by phosphorylating and inhibiting the phosphatases required for activation of CDK1, 
namely CDC25B and CDC25A (Bulavin et al., 2001; Bulavin and Fornace, 2004). The role of 
p38 in cell senescence is supported by the observation that p38
-/-
 MEFs can bypass replicative 
senescence in culture, a behavior that reminiscent of p53
-/-
 and ARF
-/-
 MEFs which are immortal 
in culture (Donehower et al., 1992; Kamijo et al., 1997; Hui et al., 2007). p38 induces apoptosis 
by transcriptional and post-transcriptional mechanisms, which may affect death receptors or 
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mitochondria-dependent apoptotic pathways through regulation on Bcl-2 proteins and p53 
(Bulavin and Fornace, 2004). However, several studies have described pro-survival roles for p38, 
which are partially mediated by the induction of cell differentiation or by anti-apoptotic 
inflammatory signals (Wagner and Nebreda, 2009). p38 knockout mice models support p38 as a 
tumor suppressor where livers from conditional p38 knockout mice develop more tumor mass and 
increased tumor size in vivo in a diethylnitrosamine-induced hepatocellular carcinoma model 
(Hui et al., 2007). Ironically, existing evidence suggests p38 possesses opposing roles as an 
oncoprotein. Increased p38 activity is observed in many types of human cancers including 
lymphoma, breast cancer and HNSCC (Neve et al., 2002; Elenitoba-Johnson et al., 2003; Riebe et 
al., 2007). In HNSCC cell lines, inhibition of p38 decreases both MMP expression and cell 
invasion (Junttila et al., 2007; Riebe et al., 2007). In addition, p38
+/-
 heterozygous mice are 
protected from lung metastases compared to wild-type mice (Matsuo et al., 2006). The oncogenic 
activities of p38 include protection of cells from apoptosis, as well as acceleration of cell 
proliferation, invasion, inflammation, and angiogenesis (Engelberg, 2004). The dual role of p38 
in tumorigenesis is difficult to explain given sufficient conflicting data supporting both roles. It 
has been suggested that whether p38 functions as a tumor suppressor or oncogene likely depends 
on cellular context or tumor type, stage and perhaps most importantly, on the accompanying 
pathway activation or inactivation. 
 
To better understand LZAP biological activities and to gain mechanistic insight, additional LZAP 
binding partners have been sought. A Scan Site Search (http://scansite.mit.edu/) using LZAP 
sequence revealed that LZAP contains sites predicted to bind to the common MAPK domain- 
docking domain (D domain). In vivo binding assays reveals interaction of LZAP with p38α 
MAPK, and immunofluorescent staining of expressed proteins shows p38α co-localizes with 
LZAP in the nucleus. LZAP expression is associated with a dose dependent decrease in p38 
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phosphorylation and activity, both at basal level and following cytokine stimulation. Conversely, 
siRNA-mediated loss of LZAP increases p38 phosphorylation and activity after cytokine 
treatment indicating that LZAP regulates p38 phosphorylation at basal levels. Mechanistically, 
LZAP does not decrease p38 phosphorylation of p38 based on inhibition of upstream kinases 
MKK3 or MKK6. 
 
LZAP and Wip1 phosphatase 
Our data describing LZAP regulation of RelA and p38 phosphorylation combined with data from 
others showing that LZAP decreases Chk1/2 phosphorylation suggest that a common effect of 
LZAP expression is to decrease phosphorylation of its bound proteins. A search of the literature 
identified two phosphatases (Wip1 and PP2A) that are responsible for dephosphorylation of RelA 
at Ser536 (Chew et al., 2009). Remarkably, Wip1 substrates include p38 and Chk1/2, which 
remarkably, are also LZAP regulated binding partners (Lu et al., 2008). 
 
Aberrant or excessive kinase signaling is considered a hallmark of cancers, including HNSCC 
(Pomerantz and Grandis, 2004). Because kinases were initially thought to be more specific than 
phosphatases, kinases were viewed as more appropriate targets for anti-cancer therapies and have 
been more intensely studied (Lammers and Lavi, 2007). Compared to kinases, phosphatases have 
been less intensely studied and characterized, even though they are greatly implicated in 
tumorigenesis. Protein phosphatases can be broadly categorized based on their substrate 
specificity into tyrosine phosphatases or serine/threonine phosphatases. Metal-dependent protein 
phosphatases (PPM) are a subset of serine/threonine kinases distinguished by their requirement of 
divalent cations such as Mg
2+
 or Mn
2+
 for their activities and by their insensitivity to inhibition by 
the phosphatases inhibitor okadaic acid (Lammers and Lavi, 2007). A single family of 
phosphatases, PP2C, comprises the PPM group. Because the PP2C family members WIP1 and 
PPM1B are implicated in our future work, and these phosphatases have been implicated in 
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tumorigenesis, our focus will be limited to this phosphatase subgroup (Tamura et al., 2006; 
Lammers and Lavi, 2007). Regulation of PP2C activity is thought to be primarily through 
regulation of protein levels, post-translational modification, and subcellular compartmentalization 
(Lammers and Lavi, 2007). 
 
Wip1 (also known as PPM1D and PP2Cδ) was identified in a screen to detect p53-responsive 
genes and named because it is a wild-type p53-induced phosphatase (Fiscella et al., 1997). Wip1 
is a member of the PP2C family of serine/threonine phosphatases and has been extensively 
studied largely because of its role as an inhibitor of p53 working through a negative feedback 
loop. Many proteins have been identified as Wip1 substrates and common substrate recognition 
sequences have also been identified. The majority of Wip1 targets contain either TXY motifs, 
where X can be any amino acid or S/TQ motifs. The S/TQ motifs containing proteins that Wip1 
targets for dephosphorylation are all phosphorylation targets of ATM or ATR, including p53, 
Chk1, Chk2, ATM, MDM2 and γH2AX (Lu et al., 2008; Cha et al., 2010). p53 is the most well-
known and well-studied Wip1 target and inhibition of p53 by Wip1 occurs through five 
mechanisms (Fig. 1.3). The most direct mechanism through which Wip1 inactivates p53 is 
through dephosphorylation of p53 at Ser15 (Lu et al., 2005). Additionally, Wip1 
dephosphorylates MDM2 at Ser395, an ATM phosphorylation site, leading to MDM2 activation 
(Lu et al., 2007). Additionally, Wip1 dephosphorylates and inactivates p38 kinase activity thereby 
inhibiting p53 activating phosphorylation on Ser33 and Ser46 (Takekawa et al., 2000). Finally, 
Wip1 dephosphorylates and inactivates both ATM and its target Chk2 (Lu et al., 2005; Shreeram 
et al., 2006). ATM and Chk kinases phosphorylate p53 on Ser15 and Ser20 respectively, resulting 
in activation and stabilization of p53 (Banin, 1998; Shieh et al., 2000). Collectively, these data 
suggest that the major target of Wip1 is p53 with resultant destabilization and inactivation of p53 
by dephosphorylating p53 directly or indirectly through p53 regulatory proteins. The biologic 
consequences of p53 inactivation lead to diminished cell cycle arrest and apoptosis in response to  
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Figure 1.3. p53 is a major target of the Wip1 phosphatase 
Wip1 inhibits p53 through direct dephosphorylation of p53 and through dephosphorylation of 
p53 activators and inhibitors. p53 inhibitors (MDM2 and Wip1) are represented in red oval 
and p53 activators (p38, Chk2, and ATM) are represented in green oval. Note that 
dephosphorylation of MDM2 at serine 395 by Wip1 is an activating event. In contrast, 
dephosphorylation of p53, ATM, Chk2, and p38 by Wip1 are inhibitory. Black arrows 
represent activation and red T shapes represent inhibition. 
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DNA damage or oncogenic stress. Although p53 is considered the major Wip1 target, there are 
many other cancer-related Wip1 targets (Takekawa et al., 2000). Wip1 exerts oncogenic activity 
through direct targeting and inhibition of p38 and Chk kinases to promote cell cycle progression 
(Bulavin et al., 2002a; Bulavin and Fornace, 2004). Additionally, MEFs derived from Wip1
-/-
 
knockout mice have decreased rates of proliferation and arrest at the G2/M transition, suggesting 
the role of Wip1 in promoting cell cycle progression (Choi et al., 2002). In addition, Wip1 
knockout mice have increased ARF and p16 transcription and expression, suggesting that Wip1 
also promotes cellular proliferation through inhibition of ARF and p16
INK4a
 (Bulavin et al., 2004). 
 
Given the direct and indirect targets of Wip1 (p53, ATM, Chk1, Chk2, MDM2, ARF, and p16), 
Wip1 has been implicated as an oncogene. Expression data from human cancers also revealed 
that the Wip1 gene is amplified in many tumor types including pancreas, lung, liver, bladder and 
breast cancers (Kallioniemi et al., 1994; Ried et al., 1994; Wong et al., 1999). RNA expression 
data from some primary human cells revealed that increased RNA expression of Wip1 correlates 
with chromosomal amplification (Bulavin et al., 2002b). Despite reports on Wip1 gene 
amplification, Wip1 protein expression data from tumors is lacking. Murine models have 
provided critical evidence in support of Wip1 as an oncogene. For instance, Wip1 knockout mice 
are partially resistant to tumor development (Harrison et al., 2004; Lu et al., 2008). Wip1
-/-
 mice 
are resistant to ErbB2- or Ras-induced mammary tumor formation (Bulavin et al., 2004). 
Conversely, mammary-specific expression of Wip1 in mice increases sensitivity to ErbB2 
mammary tumor formation, and Wip1 expressing tumor cells proliferate faster relative to cells 
from mice expressing ErbB2 alone (Demidov et al., 2007). Taken together, these data suggest that 
Wip1 alone is weakly oncogenic, but can collaborate and enhance tumor formation driven by 
other oncogenes.  
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It is established that p53 regulates Wip1 expression transcriptionally; however, no protein 
regulators of Wip1 activity or substrate specificity have been previously described. Since our data 
revealed that LZAP decreased p38 and RelA phosphorylation LZAP activity toward Wip1 was 
explored. We determined LZAP interaction with Wip1 by IP, both in vitro and in vivo. Following 
co-expression of LZAP and Wip1, immunofluorescent staining revealed that Wip1 co-localizes 
with LZAP in the nucleus. 
 
Based on a review of the reported Wip1 targets, we found that LZAP shares a large pool of 
targets with Wip1 (Table 1). The roles of LZAP and Wip1 in the regulation of RelA, Chk1/2, p53, 
MDM2, and ARF are detailed (Table 1). Two cohorts of LZAP/Wip1 targets can be identified 
based on differences in phosphorylation and activity as a result of LZAP and Wip1. Explanations 
as to why LZAP and Wip1 activity toward some targets is congruent, while activity to other 
targets diverges are largely unknown; however, tone possibility is that direct protein-protein 
interaction between LZAP and the target may determine LZAP activity toward the target. Our 
preliminary and reported data suggest that LZAP binds to Wip1 and some Wip1 substrates, such 
as p38, Chk1/2 and RelA, but not others, such as p53 and MDM2 (Wang et al., 2006, 2007a; 
Jiang et al., 2009; An et al., 2011). Noticeably, if LZAP is capable of binding to the Wip1 
substrates, LZAP and Wip1 have parallel effects on substrate activity; however, if LZAP does not 
bind to the Wip1 substrate, as is the case for p53 and MDM2, LZAP has opposite effect on 
substrate activity compared to Wip1 (Table 1). Thus, we intuitively suspect that LZAP regulation 
of Wip1 activity depends on LZAP ability to bind specific Wip1 substrates. In this model, LZAP 
binding to a Wip1 substrate would direct Wip1 toward that substrate as indicated by increased 
association between Wip1 and the substrate. This would increase substrate dephosphorylation by 
Wip1 as we reported with p38 (An et al., 2011). If LZAP cannot bind to the Wip1 substrate, then 
LZAP expression could have no effect on dephosphorylation of the substrate. However, our data 
suggest that if LZAP cannot bind to the Wip1 substrate, it has discordant activity toward the  
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substrate compared to Wip1. These data indicate that LZAP has Wip1 independent effects on the 
substrate regulation. For example, we have shown that without direct binding to p53, LZAP can 
enhance p53 phosphorylation and activation. These data suggest that LZAP may regulate Wip1 
activity. LZAP may enhance Wip1 activity to dephosphorylate oncogenic targets (e.g. MDM2) 
while simultaneously suppressing Wip1’s major oncogenic activity to inhibit p53. Given the 
opposing activities of LZAP and Wip1 toward p53 and many other common targets, it is likely 
that these aspects contribute to their disparate roles in tumorigenesis, LZAP as a tumor suppressor 
and Wip1 as an oncoprotein.  
 
Regulation of LZAP 
To date, little is known about regulation of LZAP in normal or tumor tissues. We and others have 
shown that LZAP is ubiquitously expressed in all human and mouse tissues tested, including 
pancreas, brain, liver, heart, intestine, spleen, thymus, muscle and lung (unpublished data). 
However, expression of LZAP is markedly decreased or undetectable in 30% of HNSCC, but 
mechanisms of LZAP loss are currently unknown (Wang et al., 2007a). When targeting LZAP in 
a murine model, we observed spontaneous lung tumor formation from heterozygous animals, and 
in these tumors the wild-type LZAP allele is lost (unpublished data). Human LZAP has two 
LXXLL motifs and one conserved LXXLL-like LXXFL motif. These motifs are of unknown 
significance for LZAP activity, although they are implicated to be important for nuclear hormone 
receptor co-regulator binding to steroid receptors and transcriptional co-activators (Pike et al., 
2000; MJ, 2005). Given that LZAP binds to a phosphatase, we explored post-translational 
modification of LZAP including phosphorylation that may be important for regulation of LZAP 
activity. We performed 
32
P in vivo labeling autoradiography and ubiquitination assay, suggesting 
that LZAP is a phosphoprotein and can be ubiquitinated. These data suggest that LZAP biological 
or biochemical activity may also be under the regulating of its binding partners such as MDM2 or 
Wip1 (unpublished data). 
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Summary 
Since the first description of LZAP (CDK5Rap3, C53) as a binding partner of the 35kDa CDK5 
activator binding protein p35 in 2000, a growing body of literature has demonstrated pleiotropic 
roles of LZAP. LZAP has emerged as a putative tumor suppressor and important activities and 
mechanism are beginning to be explored. Functionally, we have discovered that LZAP protein 
binds to the alternate reading frame protein ARF encoded by the INK4a gene and enhances p53 
activity in the presence or absence of ARF. Increased p53 activity following LZAP expression 
results in expression of the cyclin-dependent kinase inhibitor p21 and G1 cell cycle arrest. LZAP 
also binds and inhibits RelA resulting in decreased cellular invasion, decreased anchorage 
independent growth and decreased transcription of selective NF-κB targets including IL-8. In vivo, 
loss of LZAP accelerates tumor xenograft growth and these LZAP-deficient tumors have 
increased expression of RelA targets and increased vascularity. Mechanistically, we found that 
LZAP decreases RelA phosphorylation and inhibits NF-κB transcription. Furthermore, other 
investigators reported that LZAP binds and inhibits the checkpoint kinases, Chk1 and Chk2, 
which leads to inappropriate or early progression through the G2 and M phases of the cell cycle 
and increased sensitivity to chemotherapeutic agents. Reliant on its ability to inhibit Chk1/2, 
LZAP can activate CDC25C and further activate downstream CDK1 resulting in an early mitotic 
entry. The potential tumor suppressive activity of LZAP have continued to emerge with our 
discovery that LZAP protein expression is markedly decreased in approximately 30% of HNSCC 
and loss of LZAP is associated with increased expression of select NF-κB targets. Human tumor 
and xenograft mouse tumor data, as well as, LZAP activities as an activator of p53 and suppressor 
of RelA, suggest that LZAP may function as a tumor suppressor; however, validation of LZAP 
tumor suppressor status has been lacking. To further investigate the functions of LZAP in vivo, 
we generated transgenic mice with targeted LZAP. In these studies, heterozygous (LZAP
+/-
) mice 
were born and developed normally and are currently being investigated for inflammatory and 
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tumorigenic phenotypes. LZAP contains no identifiable enzymatic domains or other known 
motifs with enzymatic activity, suggesting that its activity may be mediated through protein-
protein interactions. We noted that without exception, all reported LZAP binding proteins are also 
targets of the Wip1. Initial exploration of Wip1 as a potential mediator of LZAP activity revealed 
that LZAP binds Wip1 and increases Wip1 association with p38, and that LZAP ability to inhibit 
p38 is at least partially dependent on Wip1.  
 
Therefore, the goals of this thesis are to determine the role of LZAP in cell cycle progression, and 
if LZAP is a bona fide tumor suppressor, to define major mechanisms explaining LZAP activity 
and regulation, and to identify the role of LZAP regulated proteins (especially p53) in 
tumorigenesis associated with LZAP loss. 
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CHAPTER II 
 
LZAP IS REQUIRED FOR EARLY EMBRYOGENESIS IN MICE AND ZEBRAFISH 
 
The majority of the work presented in this chapter is published with the title ―Tumor Suppressor 
LZAP Regulates Cell Cycle Progression Doming and Zebrafish Epiboly‖ in Developmental 
Dynamics, Jun 2011 (Liu et al., 2011). 
 
Abstract 
LZAP is a putative tumor suppressor whose expression is lost in 30% of HNSCC. LZAP interacts 
with many proteins (e.g. ARF, RelA, p38, Wip1, Chk1, Chk2) and its activities include regulation 
of cell cycle progression and response to therapeutic agents. To further investigate the functions 
of LZAP in vivo, we targeted LZAP in mice. However, homozygous knockout of LZAP in mice 
(LZAP
-/-
) resulted in early embryonic lethality. In fish and amphibians, the initial stages of 
embryonic development rely on rapid, synchronized cell cleavage of the fertilized egg, upon 
completion of cleavage cells undergo a set of morphogenetic movements collectively referred to 
as epiboly and gastrulation, providing a good model to examine earliest cell behaviors in vivo. 
Here, we explore developmental roles of the lzap gene during zebraﬁsh morphogenesis. LZAP is 
highly conserved among vertebrates, suggesting that its functional domains may be required for 
cell or organism survival. LZAP is maternally deposited so that before initiation of zygotic 
transcription, LZAP is present. While LZAP is initially ubiquitously and equally expressed during 
early development, expression of LZAP later becomes more prominent in the pharyngeal arches, 
aero-digestive tract, and brain. Antisense morpholino-mediated depletion of LZAP results in 
delay of cell synchronized cleavage and apoptosis during blastomere formation, resulting in fewer, 
larger cells. Cell cycle analyses suggest that LZAP loss in early embryonic cells causes a G2/M 
arrest. Furthermore, LZAP-deﬁcient embryos failed to initiate epiboly—the earliest 
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morphogenetic movement in animal development—which is dependent on cell-cell and cell-
matrix adhesion and likely on other signaling events that have not be described. Our results 
strongly implicate LZAP in regulation of embryonic cell cycle progression, and suggest that 
LZAP may alter adhesion and/or signaling critical for migratory activity of epithelial cell sheets 
during early development. These functions provide further insight into LZAP activity that may 
contribute not only to development, but also to tumor formation. 
 
Introduction 
LZAP (also called CDK5Rap3 or C53) was ﬁrst discovered as a binding partner of the 35-kDa 
CDK5 activator binding protein p35 (Ching et al., 2000). Activity of LZAP in association with 
p35 has not been further characterized and this interaction is likely not required for major LZAP 
activities because in mammals, CDK5 and p35 expression is restricted to central nervous system 
neurons. LZAP is ubiquitously, but variably expressed in all organs tested, including pancreas, 
brain, liver, heart, intestine, spleen, thymus, muscle, and lung (Ching et al., 2000; Wang et al., 
2006). Functionally, the LZAP protein binds to the Alternate Reading Frame protein of the 
INK4a gene locus ARF (p14
ARF
 in humans and p19
ARF
 in mice) and enhances p53 transcriptional 
activity in the presence or absence of ARF. Increased p53 activity following LZAP expression 
results in expression of the cyclin-dependent kinase inhibitor p21 and G1 cell cycle arrest (Wang 
et al., 2006). LZAP also binds and inhibits RelA resulting in decreased cellular invasion, 
decreased anchorage independent growth and decreased transcription of selective NF-κB targets 
including IL-8 (Wang et al., 2007a). Furthermore, LZAP binds and inhibits the checkpoint 
kinases, Chk1and Chk2, which leads to inappropriate or early progression through the G2 and M 
phase of the cell cycle and increased sensitivity to chemotherapeutic agents (Jiang et al., 2005, 
2009). 
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Importantly, LZAP protein expression is markedly decreased in approximately 30% of HNSCC. 
In vivo, loss of LZAP accelerates tumor xenograft growth, and human and xenograft tumors 
lacking LZAP have increased expression of RelA targets and increased vascularity (Wang et al., 
2007a). LZAP contains no identiﬁable enzymatic domains or other known motifs to suggest 
activity, indicating that LZAP activity may be mediated through protein–protein interaction. 
 
Loss of LZAP expression in HNSCC and cellular consequences of LZAP activities suggest that 
LZAP has tumor suppressor-like qualities; however, developmental roles of LZAP remain 
unexplored. Loss of LZAP renders cells, at least partially, resistant to genotoxin-induced 
apoptosis possibly through increasing ability to arrest and repair before mitotic entry. LZAP 
knockdown delays CDK1 activation and mitotic entry possibly related to increased Chk1 and 
Chk2 activity, and results in dysregulation of cell cycle progression in tumor cell lines (Jiang et 
al., 2005, 2009). 
 
Mechanisms to explain biological activities of LZAP continue to emerge. We have recently found 
that LZAP binds and inhibits activity of mitogen-activated protein kinase p38MAPK, suggesting 
another mechanism through which LZAP could alter proliferation and cell death (An et al., 2011). 
To further investigate the functions of LZAP in vivo, we generated transgenic mice targeting 
LZAP. In these studies, heterozygous (LZAP
+/-
) mice were born, developed normally, and are 
currently being analyzed for inﬂammatory and tumor phenotypes. Of note, live birth of 
homozygous knockout mice (LZAP
-/-
) has not been observed, suggesting that homozygous loss of 
LZAP results in embryonic lethality in mice (data not shown). 
 
The absence of live births of LZAP
-/-
 mice led us to explore developmental defects resulting from 
LZAP loss. Loss of homozygous mice could be attributed to embryonic lethality or placental 
problems. To begin understanding the role of LZAP in development and distinguish between 
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embryonic cellular and placental phenotypes, we turned to the zebrafish model. Zebraﬁsh are 
vertebrates whose eggs are externally fertilized, thus providing an opportunity to examine the 
earliest cell behaviors in the live embryos. This feature, combined with zebraﬁsh’s rapid 
development and transparent embryos, allows detailed in vivo description of epiboly and 
gastrulation movements (Kane and Kimmel, 1993; Montero et al., 2003; Solnica-Krezel, 2006). 
 
During the ﬁrst 3 hours post fertilization (hpf) of zebraﬁsh development, the large fertilized egg 
processes through a series of divisions without increased cytoplasm, referred to as cleavage. Cells 
are replicating DNA and rapidly dividing, resulting in an increasing number of progressively 
smaller cells. Approximately 3hpf, zygotic transcription begins, in a process referred to as the 
midblastula transition (MBT). Cells are not motile before MBT (Kane and Kimmel, 1993), but 
within an hour after MBT, they form three distinct layers: two extra embryonic lineages—an 
outer enveloping layer (EVL) and an inner dual layer, consisting of the yolk syncytial layer (YSL) 
and yolk cytoplasmic layer (YCL)—and the embryo proper between the EVL and the YSL/YCL. 
These embryonic cells, which are referred to as the deep cell layer (DCL), will give rise to 
ectoderm, endoderm, and mesoderm through the morphogenetic movements of gastrulation. 
 
Epiboly is the ﬁrst morphogenetic movement of embryonic cells. It converts a ball of dividing 
cells into a sheet of cells that spread over the yolk (Arendt and Nübler-Jung, 1999; Solnica-Krezel, 
2005). The ﬁrst visible sign of epiboly appears around 4 hpf with the ﬂattening of the blastoderm 
and doming of the yolk. As epiboly progresses, cells of EVL and forming epiblast behave as 
tightly packed epithelia with extended cell–cell interactions and continuous spatial 
rearrangements (Solnica-Krezel, 2005; Lachnit et al., 2008). Normal physiological cell death is 
not observed during these stages; however, when the process of epiboly is stalled, developing 
embryos are unable to initiate gastrulation and die. Although several genes have been implicated 
in enabling epiboly, e.g., E-cadherin (Kane et al., 2005), G proteins (Lin et al., 2009), 
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prostaglandin E 2 (Cha et al., 2006), and Pou5f1 (Lachnit et al., 2008), molecular mechanisms 
and signaling pathways important for epiboly are not well understood. 
 
To begin deﬁning the physiological role of LZAP in embryogenesis, we performed MO-mediated 
LZAP knockdown in zebraﬁsh embryos. The spatiotemporal expression of lzap was determined, 
revealing maternal deposition and high levels of expression during the initial cleavage stages. In 
organogenesis, lzap was highly expressed in pharyngeal arches, digestive tract, and brain. MO-
mediated loss of LZAP function (lzap MO) resulted in slowed progression of cell division during 
blastomere cleavage stages and absence of epiboly in the majority of morphant embryos. Analysis 
of proliferating cell nuclear antigen (PCNA), phospho-histone H3, and activated Caspase-3 
indicated that LZAP loss was associated with decreased proliferation and mitosis but increased 
apoptosis in zebrafish embryos, at a developmental stage that is not associated with apoptosis. 
Cell cycle analysis of embryonic cells suggested that loss of LZAP resulted in a G2/M arrest or 
delayed exit from G2/M. LZAP morphants initiated transcription at the MBT, suggesting that 
LZAP did not have global effects on gene expression. Hematoxylin and eosin (H&E) histological 
staining revealed loosely packed blastoderm cells indicative of disrupted cell–cell adhesion. 
These results strongly suggest that LZAP is essential for cell cycle progression and that loss of 
LZAP results in poorly adherent cells and inability to initiate epiboly. 
 
Methods 
Zebraﬁsh Lines 
Zebraﬁsh, AB strain, were raised in the Vanderbilt Zebraﬁsh Core Facility and maintained under 
standard conditions at 28°C according to the policies and procedures of the Institutional Animal 
Care and Use Committee of Vanderbilt University. Embryos were obtained by natural spawning 
and were staged according to (Kimmel et al., 1995). 
 
30 
 
Cloning of Zebraﬁsh lzap cDNA and Sequence Analysis 
A zebraﬁsh LZAP ortholog (NP_001002105) was identiﬁed by NCBI Blink search using the 
homedomain sequence of the mouse LZAP ortholog (NP_084524.1). Total RNA was isolated 
from one-cell to 120 hr post-fertilization (hpf) wild-type embryos in TRI-Reagent (Sigma). 
cDNA was synthesized from 48 hpf RNA template by reverse transcription using the iScript 
cDNA synthesis Kit (Bio-Rad) according to the manufacturer’s protocol. Transcripts of lzap were 
ampliﬁed by PfuTURBO DNA polymerase (Stratagene) and products were subcloned into pCR-
Blunt II-TOPO (Invitrogen). Primers were as follows: lzap-coding region forward: 5’-
ATGGAGAACATCCAGAATCT-3’; and reverse: 5’-TCACACATGAACTCCCATGA-3’. A 
second fragment containing the 5’-UTR and 3’-UTR regions were cloned using primers lzap-
UTR forward: 5’-GTGGAAATGTAAACTTGTGC-3’; and reverse: 5’-
TGATGCATATGTGCAGCTTG-3’. The identity of the cloned zebraﬁsh lzap gene was veriﬁed 
by sequencing in the forward and reverse directions by the Vanderbilt Sequencing Facility. 
 
Quantitative RT-PCR 
Total RNA was extracted from approximately 100 embryos at different embryonic time points 
using the TRIzol reagent (Sigma). A total of 50 ng of RNA was used per 20 μL reaction and 
performed by iScript One-Step RT-PCR Kit with SYBR Green on a Bio-Rad iCycler IQ 
according to the manufacture instructions. Sequences of primers were as follows: lzap-3’-UTR 
forward: 5’-GTGAAGAAGGCGACTTGGTG-3’; and reverse: 5’-
TGATGCATATGTGCAGCTTG-3’. β-actin was used as a baseline expression using primers 
forward: 5’-GACTCAGGATGCGGAAACTG-3’; and reverse: 5’-
GAAGTCCTGCAAGATCTTCAC-3’. Three independent experiments in triplicates were 
performed. ∆∆C(T) Method was used to analyze relative gene expression data. lzap expression 
fold change was normalized to β-actin and relative quantity was normalized to 1-cell stage. 
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Morpholino Oligonucleotides and mRNA Microinjections 
Antisense morpholino (MO) speciﬁcally targeting the 5’-UTR of LZAP was designed and 
purchased from Gene Tools, LLC (Philomath, OR). An additional MO oligonucleotide was 
designed to target the ATG start codon. This ATG MO at 8 ng caused the same morphologic 
phenotype as 5’-UTR MO at 4 ng dose, therefore, we used the later in all presented experiments. 
The sequences of the morpholino oligonucleotides were: lzap-5’-UTR MO: 5’- 
AAGAATTACTAAAACGACCCCATGC-3’ (targets bases -54 to -30); 5-base pair mismatch 
control morpholino: 5’- AACAATTAGTATAACCACCCCATCC-3’, and lzap-ATG morpholino: 
5’-AGGGAGATTCTGGATGTTCTCCATT-3’ (targets bases -1 to 24). A validated MO 
targeting zebraﬁsh p53 (5’-GCGCCATTGCTTTGCAAGAATTG-3’) was obtained from 
Gene Tools (Robu et al., 2007). 
 
The full-length cDNA of lzap was ampliﬁed by PCR and subcloned into the pCS2+ expression 
vector. Additional constructs used in this study were pCS2+-lzap:3HA (3×hemagglutinin tag 
added to the 3’-end of lzap coding sequence) and pCS2+-lzap:CDs (lzap cDNA lacking the 
5’-UTR subcloned into pCS2+ vector) for rescue experiments. Capped RNA (cRNA) was 
synthesized from expression constructs using the mMessage mMachine kit (Ambion) according 
to the manufacturer’s instructions and RNA quality was assayed using gel electrophoresis. RNA, 
MO, or both combined were dissolved in distilled water and injected into the yolk of 1-to 2-cell 
stage embryos as described (Montero-Balaguer et al., 2006). Effective and speciﬁc doses of MOs 
and cRNA were determined by titration, reporter constructs and rescue experiments. Used 
concentrations are provided with each experiment. 
 
Whole-Mount In Situ Hybridization 
Whole-mount in situ hybridization using Dig-labeled RNA probes was performed as previously 
described (Barrallo-Gimeno et al., 2004). For probe synthesis, lzap was cloned into pCR-Blunt II-
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TOPO, the vector was linearized with BamHI and antisense probes were synthesized with T7 
RNA polymerase (Ambion). Hybridization and washing were performed at 63°C. 
 
Histological and Immunohistochemical Analysis 
Staged zebraﬁsh embryos were ﬁxed overnight in 4% paraformaldehyde then embedded in 
parafﬁn, sectioned at 5 μm thickness and stained with hematoxylin and eosin (H&E) for 
histological analysis. To determine cell proliferation, mitotic and apoptotic rates, 
immunohistochemical stain for proliferating cell nuclear antigen (1:15,000 dilution, Sigma-
Aldrich), p-Histone H3 (1:400 dilution, Cell Signaling Technology), and active Caspase-3 (1:300 
dilution, BD Pharmingen) were performed respectively as described previously (Yin et al., 2008). 
The immunostained slides were examined by light microscopy. Cell proliferation, mitosis, and 
apoptosis were assessed as PCNA, p-Histone H3, and active Caspase-3 labeling index (LI), 
respectively. For each embryo, the index was deﬁned as the percentage of immune-positive 
embryonic cells of PCNA, p-Histone H3 or active Caspase-3 in total embryonic cells respectively. 
For each LI, 20 representative embryos were evaluated at higher power magniﬁcation (× 40), and 
the average was calculated. The data for the PCNA, p-Histone H3, or active Caspase-3 LI were 
presented as mean ± standard deviation (SD). 
 
Immunoﬂuorescent Staining and TUNEL Labeling 
Whole-mount immunoﬂuorescent staining was performed as described (Pfaff et al., 2007) using 
polyclonal Ser-10 p-Histone H3 (1:750 dilution, Santa Cruz) and monoclonal α-tubulin (1:500 
dilution, Sigma) detected with Alexa Fluor ﬂuorescently conjugated secondary antibody (1:600 
dilution, Molecular Probes). For nuclear counterstain, embryos were incubated with TO-PRO-3 
(1:1,000 dilution, Molecular Probes) for 30 min. Confocal images were taken with a Zeiss 
LSM510 inverted confocal microscopy (Vanderbilt Cell Imaging Shared Resource). For TUNEL 
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staining, embryos were dechorionated and ﬁxed at 6 and 12 hpf and apoptotic cells visualized by 
in situ cell death detection kit (Roche). 
 
Fluorescence-Activated Cell Sorting Analysis of DNA Content and Nocodazole Treatment 
MO-injected zebraﬁsh embryos were transferred from 28°C and manipulated in ice-cold Ca2+-free 
Ringer solution. For cell cycle inhibition, embryos were treated with nocodazole, 10 μg/ml for 30 
min (Sigma). After termination of this treatment, the embryos were washed with Ca
2+
-free Ringer 
solution, 0.05% DMSO (Horowitz et al., 1983), then incubated in egg water for 15 or 30 min. 
Embryos were dechorionated by pronase, and yolks mechanically disrupted. The embryonic cell 
mass was then trypsinized, and isolated embryonic cells were stained with PI, ﬁltered through 
Cell Strainer Cap (BD), and cell cycle analyzed by ﬂuorescent ﬂow cytometric analyses as 
previously described (Yarbrough et al., 2002). Cell clusters and debris were manually excluded 
leaving only isolated single cells for analyses. Cell cycle analyses were performed on a 
FACSCalibur machine (Becton Dickinson) and analyzed using CellQuest Pro software. 
 
Statistics 
Results in graphs represent mean ± SD or as indicated. Statistical signiﬁcance was determined by 
unpaired two-tailed Student’s t-test (Excel or Prism Software), with p < 0.05 considered as 
signiﬁcant. 
 
Results 
LZAP Is Highly Conserved Across Species 
Using in silico data mining of NCBI databases, sequences encoding LZAP orthologs were aligned, 
revealing that they are highly conserved in multicellular organisms including vertebrates, 
invertebrates and plants, but not in unicellular yeast and bacteria. The zebraﬁsh lzap gene spans 
9.3 kb of genomic sequence and is located on zebraﬁsh chromosome 12 (Fig. 2.1A). The full- 
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Figure 2.1. lzap Is Highly Conserved During Evolution 
(A)  Gene structure of zebrafish lzap located on chromosome 12. Filled boxes represent exons. 
Cen, centromere; Tel, telomere. 
(B)  Alignment of human, mouse, and Zebrafish Lzap protein sequences. Amino acid 
sequences of LZAP orthologs from the NCBI database were aligned and similarity 
assigned based on the Clustal W algorithm. Hs, Homo sapiens (NP_788276.1); Mm, Mus 
musculus (NP_084524.1); Dr, Danio rerio (NP_001002105.1). (*) identical; (.) conserved; 
(:) semi-conserved. 
(C)  Pairwise comparison of amino acid conservation between human (H. sapiens), mouse (M. 
musculus), and zebrafish (D. rerio) LZAP. 
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length cDNA of the lzap gene was ampliﬁed using gene-speciﬁc primers and total RNA from 
zebraﬁsh wild-type AB strain as template. A 1,524-bp transcript comprised the full-length cDNA 
and encoded a protein consisting of a predicted 507 amino acid residues. Sequence alignment 
demonstrated that the zebraﬁsh LZAP protein is highly similar in composition and length to the 
human and murine orthologs. Similarity between zebraﬁsh LZAP and either human or murine 
LZAP is greater than 80%, and between murine and human LZAP is more than 90%, indicating 
that structural, and likely functional aspects of LZAP have been highly conserved during 
evolution (Fig. 2.1B and C). Sequence alignment suggests that the amino-terminal portion (amino 
acids 1-122) and carboxyl-terminal (amino acids 412-terminus of LZAP) domain are even more 
faithfully conserved, suggesting that these areas may represent domains of the LZAP protein that 
are critical for functions. 
 
Homozygous Floxed LZAP Alleles Results In Embryonic Lethality In Mice 
To create the conditional LZAP knockout mouse, the LZAP gene was targeted in murine ES cells 
through homologous recombination by electroporation using a targeting vector with two loxP 
sites, one engineered 564 bp 5’ of the initiating ATG (155 bp 5’ of the predicted proximal 
promoter) and another in the second intron. The general schema including loxP sites (arrowheads), 
LZAP gene structure including 14 exons, and LZAP mRNA are shown (Fig. 2.2A). Two 
recombinant clones (2A2 and 2G5) were selected by PCR and Southern blotting (Fig. 2.2B), 
injected into blastocysts and resultant F0 chimeric mice crossed with C57Bl/6 mice. Insertion of 
loxP sites was confirmed on F1 generation mice by PCR and sequencing (Fig. 2.2C and data not 
shown). 
 
The Neo cassette had been deleted from the 2A2 clone, but not the 2G5 clone before creation of 
the chimera. The 2G5 clone mice were crossed with ACTFLPe expressing mice expressing FLP1 
recombinase under the human ACTB promoter (Jackson Laboratory) for removing the Neo  
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Figure 2.2. Targeting LZAP in Mice 
(A)  Design of conditional lzap allele. Using homologous recombination in murine ES cells, 
two loxP sites were inserted into the LZAP gene as indicated. 
(B)  Southern blotting of recombinant ES cells. DNA from wild-type mouse liver (lane 1) or 
from independent ES cells clones 2A2 and 2G5 after homologous recombination (lane 2 
& 3) was digested with HindIII and ScaI, separated by electrophoresis and Southern 
blotting performed with a [
32
P]-labeled probe specific to the 1
st
 exon of the LZAP gene. 
(C)  PCR genotyping of wild-type and LZAP
flox/+ 
mice. DNA isolated from tails of mice 
derived from crosses of 2A2 chimeric mice with C57Bl/6 mice was PCR amplified using 
primers surrounding loxP2. Floxed and wild-type alleles are indicated (size difference is 
based on presence or absence of loxP). 
(D)  Numbers and percentages of wild-type and heterozygous, male and female mice pups that 
were produced from crosses between heterozygous males and females. 
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cassette. All data reported were derived from the 2A2 clone unless specified; however, critical 
results were confirmed using the 2G5 clone in independent experiments. All mice derived from 
2A2 and 2G5 clones were bred with EIIa-Cre expressing mice (Jackson Laboratory) to delete the 
floxed-sequence. Mice heterozygous for LZAP (LZAP
+/-
) were identified in the F1 generation and 
crossed to generate mice homozygous for loss of both LZAP alleles (LZAP
-/-
); however, of more 
than 200 mice born to LZAP
+/-
 crosses, no LZAP
-/-
 mice were identified. Wild-type (LZAP
+/+
) 
and heterozygous (LZAP
+/-
) mice were observed in litters at the normal Mendelian frequency of 
1:2 (Fig. 2.2D). There was no obvious sex ratio bias and LZAP
+/-
 mice developed, grew, and 
reproduced normally. Although not yet thoroughly described, LZAP
+/-
 mice may have skin 
inflammatory phenotypes that are more severe than normal for the C57BL/6 mice strain. To 
determine the developmental stage of death for LZAP
-/-
 embryos, dissection of pregnant females 
from LZAP
+/-
 crosses was performed starting at embryonic day 14.5 (E14.5) and regressing to 
E5.5 (data not shown). Even at the earliest developmental day examined, no LZAP
-/-
 embryos 
have been observed. These data suggest that embryonic death in LZAP
-/-
 mice is early during 
embryonic development.  
 
Based on known LZAP binding partners and activities, explanations of embryonic lethality in 
LZAP
-/-
 mice were not obvious. Although the phenotype of embryonic lethality was observed in 
mice derived from independent clones of ES cells after homologous recombination, it was 
possible that the phenotype was due to aberrant targeting of the LZAP construct or disruption of 
noncoding RNA, or other unanticipated effects not related directly related to loss of LZAP. Also, 
in mammals embryonic lethality can be related to placental issues independent of effects on 
embryonic development. To probe these issues, we examined developmental effects of LZAP loss 
in Danio Rerio (Dr, zebrafish). Because development is more easily observed in zebrafish than 
mice and placental development is not an issue, MO was utilized. MOs decrease protein 
expression through interruption of translation but do not alter or disrupt gene expression at the 
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mRNA level. Thus, we used this complementing method in a different species to confirm findings 
from LZAP
-/-
 mice, and to determine if loss of LZAP expression results in a developmental 
phenotype and, if so, at what developmental stage.  
 
lzap Is Expressed During Epiboly and Organogenesis 
To determine timing and relative magnitude of lzap expression during development, quantitative 
reverse transcriptase-polymerase chain reaction (qRT-PCR) using exon-spanning lzap-speciﬁc 
primers was performed on total RNA isolated from whole embryos at developmental stages 
ranging between one-cell and 5 dpf (Fig. 2.3A). lzap is expressed during all developmental stages 
examined. When normalized to β-actin, lzap expression decreases during gastrulation. 
Interestingly, our results indicate that expression of lzap is dramatically up-regulated at 12 hpf. 
Because there is no ideal gene for normalization during very early development (Tang et al., 
2007), and β-actin expression is low at one-cell stage and increases with development in a time- 
dependent manner before shield stage (Cao et al., 2004; Duffy et al., 2005), the normalized 
quantiﬁcation of expressed lzap during very early development (< 6 hpf) may be overestimated. 
To begin exploring cellular, tissue, and organ localization of lzap transcripts, we performed in 
situ hybridization on zebraﬁsh whole-mount embryos representing the same developmental stages 
as examined by qRT-PCR (Fig. 2.3B–L). Maternal deposition and ubiquitous expression of lzap 
is observed throughout cleavage stages (Fig. 2.3B and C). lzap is widely expressed in early 
epiboly (Fig. 2.3D), but at 12 hpf expression of lzap is restricted to the prechordal plate in an area 
corresponding to hatching gland at Prim stages (Fig. 2.3E–G). lzap expression is ﬁrst detected in 
the central nervous system, eye, and mesoderm at 24 hpf, and expression persists throughout the 
second day of development (Fig. 2.3G and H). At 3 dpf, lzap transcripts are detectable in the 
region of the developing pharynx, pharyngeal arches and in the primordia of the gastrointestinal 
organs (Fig. 2.3I). As development progressed, lzap expression persists in the pancreas and 
gastrointestinal tube, jaw and pharynx region, tectum, and the hindbrain regions (Fig. 2.3J and K).  
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Figure 2.3. lzap is Expressed During Epiboly and Organogenesis 
(A) Relative expression of lzap mRNA in developing fish embryos. lzap expression was 
determined by qRT-PCR at indicated developmental stages and normalized to β-actin 
expression. 
(B–K) Representative photographs of lzap expression during development as determined by in 
situ hybridization. Embryos are depicted in lateral view, except for the animal pole view 
shown in F’. 
(B–D) Ubiquitous expression of maternal lzap was detected throughout cleavage stages (B,C) 
and expression was maintained into early epiboly (D). 
(E, F) After epiboly from 9–12 hpf, lzap expression was concentrated in the precordal plate 
and areas corresponding to the future hatching gland. 
(G, H) At 1 dpf to 2 dpf lzap expression was more intense in the central nervous system, eye, 
and pharyngeal region. 
(I) lzap staining was visible in the developing pharynx region, pharyngeal arches and in the 
primordial of the gastrointestinal organs at 3 dpf. 
(J, K) lzap mRNA was detected at 4–5 dpf (J,K) in the pancreas and gastrointestinal tube, jaw 
and pharynx region, tectum, gills (see inset, K), and the hindbrain regions. 
(L) Negative control with sense probe at 3 hpf reveals no staining. 
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Speciﬁcally, lzap expression appears to be present in pharyngeal arch epithelia at 4 and 5 dpf, in 
structures that will contribute to the epithelia of the future gills (Fig. 2.3K). The 1.6-kb-long 
antisense RNA probe used for in situ hybridization experiments spans the full-length cDNA. The 
equivalent probe transcribed in the sense orientation was used as a control and does not detect 
expression (Fig. 2.3L). 
 
Morpholino-Mediated Depletion of LZAP Results in Epiboly Defects 
To investigate the function of LZAP during development, we generated loss-of-function zebraﬁsh 
morphants by injection of antisense oligonucleotides into one-cell stage embryos to block protein 
translation. The lzap morpholino (MO) corresponded to sequences within the 5’ untranslated 
region (UTR) and was designed to target both maternal and zygotic transcripts. A MO 
corresponding to the lzap 5’ UTR targeting MO but with a 5-bp mismatch was used as control. 
Several antibodies recognizing mammalian LZAP were tested for reactivity with zebraﬁsh LZAP 
protein; however, none recognized zebraﬁsh LZAP by either immunoblotting or immunostaining. 
In addition, full-length zebraﬁsh LZAP was used to make rabbit polyclonal antibodies. 
Unfortunately, initial bleeds of the rabbits revealed no speciﬁc antibodies. Therefore, to 
determine effectiveness and speciﬁcity of the 5’ UTR MO, an expression construct that includes 
the 5’ UTR sequence targeted by the MO, the lzap open reading frame, and three HA tags at the 
C-terminus (lzap:3HA, Fig. 2.4A) was used to measure effectiveness of lzap MO. Expression of 
HA-tagged LZAP from the lzap:3HA construct is detectable in 89% of injected embryos by 4 hpf 
without developmental dysmorphology, as assessed by direct immunoﬂuorescence with 
antibodies against the HA tag. To estimate the minimal effective concentration of MO capable of 
inhibiting LZAP expression, in vitro synthesized lzap:3HA mRNA and increasing MO doses (2 
ng, 4 ng, or 6 ng) were co-injected, and HA-tagged LZAP expression was determined by 
immunoﬂuorescence (Fig. 2.4B). Following injection of 2 ng of MO, expression of HA-tagged 
LZAP is decreased in approximately 50% of injected embryos and is undetectable in the  
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Figure 2.4. Morpholino-mediated Depletion of LZAP Results In Cleavage Stage and 
Epiboly Defects 
(A)  Schematic representation of lzap RNAs. lzap:3HA contains the 5’ UTR sequence targeted 
by the lzap MO and was used to confirm MO effectiveness. lzap:CDs contains the entire 
lzap coding sequence but lacks the MO target sequence and was used for rescue. 
(B)  Verification of on-target and dose-dependent effects of lzap MO on exogenous LZAP 
expression. Embryos were injected with lzap:3HA singly or with increasing amounts of 
lzap MO visualized by immunofluorescence 4 hpf. No immunofluorescence was observed 
in control embryos lacking the primary antibody (data not shown). 
(C)  Schematic showing incidence of developmental defects and nonviable embryos at 
indicated time points following injection of lzap MO, control MO or in embryos without 
injection. 
(D–E‖) lzap specific MO or control was injected and viability and morphology determined by 
microscopic visualization at indicated times. Results were compared with uninjected 
embryos. (D–H) Lateral view of uninjected embryos from 3–24 hpf. 
(D’–H’, D‖–E‖) Lateral view of lzap MO injected embryos. Embryos were time matched to 
uninjected embryos. Arrows indicate persistence of the syncytial layer. Mild and severe 
phenotypes following injection of lzap MO are shown. 
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remainder. After injection of 4 ng and higher concentrations of lzap MO, HA-tagged LZAP could 
not be detected by immunoﬂuorescence in essentially any injected embryos. Because 4 ng of lzap 
MO was the lowest effective dose that consistently ablates exogenous LZAP expression, it was 
used in all following experiments. 
 
Consistent with early expression of LZAP (Fig. 2.3), the morphant phenotype was observed 
before the MBT, the time marking onset of zygotic transcription. At 3 hpf, lzap morphants could 
be categorized as follows: (i) normally developing embryos (18%), (ii) dead embryos (33%), and 
(iii) abnormal embryos (49%). Abnormal morphant embryos could be further categorized as 
either mildly or severely abnormal (Fig. 2.4C). At 3 hpf, development of morphant embryos with 
a mild phenotype lags the wild-type embryos by approximately 40 min, and the severely 
abnormal morphants are even further delayed (Fig. 2.4D–D‖). At 6 hpf, nearly all MO injected 
embryos present a phenotype, and 56% of injected embryos are dead. Surviving morphant 
embryos at 6 hr fail to dome, which normally occurs at 4 hpf, and remain at the sphere stage 
(Fig. 2.4E–E‖). In animals with mild phenotype, epiboly proceeds up to the yolk plug closure, 
albeit at a slower pace than in uninjected controls. Of lzap morphant embryos, the severe 
phenotype is most common with embryos reaching oblong stage (3.7 hpf) (Fig. 2.4E‖), where 
they persist for up to 12 hpf before degenerating. In contrast, the mild category morphants 
complete gastrulation, undergoing involution, dorsal convergence and limited extension before 
dying between 12 and 24 hpf. The majority (80%) of the embryos injected with comparable dose 
of the control MO develop normally (Fig. 2.4C), and no differences were observed between 
uninjected embryos and embryos injected with control MO. 
 
Epiboly Defects in lzap Morphants Can Be Rescued by Co-injection of lzap mRNA 
To exclude off target effects and to verify MO speciﬁcity, as well as to implicate LZAP in the 
extensive developmental delay observed in lzap morphants, rescue experiments were performed 
43 
 
using synthetic lzap:CDs mRNA that contains full-length lzap open reading frame but lacks MO 
target sequences within the 5’ UTR (Fig. 2.4A). Injection of 100 pg of the capped lzap:CDs 
mRNA does not result in developmental dysmorphology (not shown), but co-injection of 
lzap:CDs mRNA with 4 ng of lzap MO signiﬁcantly improves morphants’ survival during the 
ﬁrst 24 hr of development and accelerates gastrulation to almost normal rates (Fig. 2.5A–F). 
Morphant rescue with lzap mRNA increases the percentage of live embryos from 67% to 94% at 
3 hpf, from 44% to 81% at 6 hpf and from 12% to 38% at 24 hpf (Fig. 2.5G). There is a 
signiﬁcant loss of embryo viability in the rescued group co-injected with lzap MO and lzap 
mRNA between 6 hpf and 24 hpf; however, compared with the lzap MO group, embryo viability 
following lzap mRNA remains signiﬁcantly improved. It is possible that expression of LZAP 
may inhibit cellular or embryo viability between 6 and 24 hpf. Alternatively, lethality following 
co-injection of lzap MO and mRNA may be due to longer stability of MO compared with co-
injected synthetic mRNA. Taken together, these results indicate that the observed phenotypes are 
due to depletion of LZAP and suggest that endogenous LZAP expression is critical for normal 
development and survival in the early embryo. 
 
We and others have previously shown that LZAP regulates mitotic entry, cell cycle progression 
and genotoxin-induced apoptosis, likely through its interaction or regulation proteins involved in 
apoptosis and cell cycle: p53, p38, Chk1/2 and CDK1 (Jiang et al., 2005; Wang et al., 2006; An et 
al., 2011). To begin exploring potential cellular mechanisms mediating LZAP function, we 
analyzed cellular proliferation, mitosis, and apoptosis in lzap MO-injected and rescued embryos. 
At 6 hpf, proliferation of embryonic cells is determined by staining for expression of PCNA, 
mitosis by staining for phospho-histone H3 (p-Histone H3), and apoptosis by staining for 
expression of activated (cleaved) Caspease-3. Three groups of uninjected-, 4 ng of MO injected-, 
and 4 ng of MO / 100 pg of lzap RNA co-injected-embryos were collected for analysis at 6 hpf 
(Fig. 2.5H and 2.6A). 
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  Figure 2.5. Cleavage Stage and Epiboly Defects in lzap Morphants are Rescued by Co-
injection of lzap mRNA 
(A–F) Co-injection of lzap mRNA with 5’UTR MO partially rescued developmental defects 
of lzap morphants at 6 and 24 hpf. 
(G) Schematic showing embryo viability at indicated time points following injection of lzap 
MO with or without lzap RNA. Data represent means and standard errors derived from 
more than 180 embryos from three independent experiments. 
(H) lzap morphants display proliferative, mitotic, and apoptotic defects that are partially 
rescued through co-injection of lzap mRNA. Embryos were analyzed at 6 hpf by IHC 
staining using antibodies to PCNA, p-Histone H3, and cleaved Caspase-3 as indicated 
(original magnification, ×40). 
(I–L) Indices for proliferation (I), mitosis (J), and apoptosis (K) were determined by dividing 
the number of cells staining for PCNA, p-Histone H3, or cleaved Caspase-3, respectively, 
by the total number of cells. Means and standard error are presented. Data are from 
sections of 20 independently injected embryos. For relative cell size determination, cell 
borders were marked on captured hematoxylin stained images and relative area (L) 
calculated by ImageJ software. Values are normalized to control cells. NS, not significant. 
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PCNA is a subunit of DNA polymerase that plays a critical role in DNA replication. Cells were 
scored as proliferating if PCNA staining was detected within the nucleus. Proliferative index was 
calculated by dividing PCNA-positive cells by total number of cells examined. At 6 hpf, cells 
PCNA expressing cells were observed throughout embryos in uninjected controls, lzap morphants, 
and lzap mRNA rescue groups; however, the proliferative index of lzap morphants is signiﬁcantly 
decreased compared with controls (92% vs. 56%, p < 0.01). Proliferative index is partially 
restored (56% vs. 77%, p < 0.01) following rescue through co-injection of lzap mRNA with MO 
(Fig. 2.5H, 2.5I and 2.6A). 
 
To further support ﬁndings of differences in cellular proliferation as indicated by PCNA 
expression, expression of p-Histone H3 as a marker of mitosis was determined using 
immunohistochemistry (IHC) and immunostaining. Mitotic index was deﬁned by dividing the 
number of p-Histone H3-positive cells by the total number of cells examined (Fig. 2.5H, 2.5J and 
2.6A). Consistent with proliferation data as measured by PCNA, the mitotic index reveals that 
mitoses are signiﬁcantly reduced in lzap morphants compared with controls (16% vs. 6%, p < 
0.01). Rescue by co-injection of lzap mRNA signiﬁcantly increases mitosis compared with lzap 
morphants (6% vs. 11%, p < 0.05) but does not restore mitotic index to the level observed in 
control embryos (11% vs. 16%, p < 0.05). 
 
To measure apoptosis within embryos, IHC was performed using antibodies speciﬁc to cleaved 
Caspase-3, and apoptotic index was determined by dividing Caspase-3–positive cell number by 
total number of cells examined (Fig. 2.5H and K). Consistent with reports which show that during 
normal development apoptosis is not observed before gastrulation (Yamashita, 2003; Granero-
Moltó et al., 2008), no apoptotic cells are detected in control embryos at 6 - 30 hpf (Fig. 2.5H, 
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2.6B and 2.6C). However, following lzap MO injection, 7% of cells express cleaved Caspase-3 as 
a marker of apoptosis (0% vs. 7%, p < 0.01). Co-injection of lzap morphants with lzap mRNA 
signiﬁcantly decreases the apoptotic index from 7% to 2% (p < 0.05). The presence of apoptosis 
in lzap morphants at 6 and 12 hpf was conﬁrmed by TUNEL (terminal deoxynucleotidyl 
transferase–mediated deoxyuridinetriphosphate nick end-labeling) assay (Fig. 2.6C). We have 
also independently further supported these results in live embryos stained with Acridine Orange, 
where we observed a specific and abnormal accumulation of dying cells in the central nervous 
system, eye and mesoderm at 30 hpf in lzap morphants (Fig. 2.6B). These data suggest that MO-
directed knockdown of LZAP during early and later embryogenesis increases activity of the 
intrinsic apoptosis pathway resulting in abnormal apoptosis. Although potentially contributing to 
embryonic lethality, it should be recognized that the relatively low levels of cellular apoptosis 
observed in lzap morphant embryos may not be the sole contributor to embryonic death in lzap 
morphants. Although not explored, it is possible that necrosis may contribute to observed early 
embryonic death given reports describing necrosis in embryos failing to initiate epiboly, 
regardless of the precipitating defect responsible for inhibition of epiboly (Kishimoto, 2004; 
Reim and Brand, 2006). 
 
In addition to cellular phenotypes of proliferation, mitosis, and apoptosis in morphant embryos, 
histological evaluation reveals a noticeable difference in cell number, cell size, and cell adhesion 
compared with control embryos (Fig. 2.5H and 2.6A). Relative cell size was quantiﬁed in H&E 
stained control, morphant and rescued embryos by ImageJ software (NIH) at 6 hpf. The mean cell 
size for morphant embryos is signiﬁcantly greater when compared with cells from control 
embryos (1.5-fold; p < 0.05) (Fig. 2.5L). Although rescue with lzap mRNA partially corrects 
proliferation, mitosis and apoptosis defects caused by lzap MO, expression of lzap does not 
restore the cell size abnormality observed in the morphant embryos. Larger cell size and fewer  
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Figure 2.6. lzap Morphants Display Proliferative, Mitotic and Apoptotic Defects 
(A)  Embryos were analyzed at 6 hpf by IF staining using antibodies to PCNA (green) and p-
Histone H3 (red). Cells were also stained with DAPI (nuclear staining, blue). 
(B)  Detection of dying cells by Acridine Orange staining of non-injected and lzap MO 
injected embryos at 30 hpf (lateral views). 
(C)  TUNEL staining was used to identify apoptotic cells (indicated by arrows) at 6 and 12 
hpf. Apoptosis was observed in scattered cells within the embryo after lzap depletion, 
while no apoptosis is detected in uninjected controls. At 12 hpf, apoptotic cells were 
observed primarily in rostral locations in control embryos, while apoptotic cells were 
more widely dispersed in lzap morphants. 
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nuclei were observed throughout the ﬁrst 6 hpf, suggesting that LZAP may be required for normal 
cell cycle progression or cell cleavage. 
 
Dividing cells before the MBT are not motile, but within an hour after onset of MBT, they begin 
epiboly and generate a sheet of epithelial-like cells. This cellular layer provides material for 
morphogenetic movements of gastrulation with resultant formation of germ layers. Motility of 
these cells has been shown to be dependent on cell adhesion molecules including E-cadherin 
(Kane et al., 2005; Shimizu et al., 2005). Notably, sections of early lzap morphant embryos reveal 
gaps between cells, which were not observed in controls or in morphants rescued by injection of 
lzap mRNA. Although intercellular spaces in lzap morphant embryos could be an artifact of 
ﬁxation, the fact that they were not observed in control or rescued embryos suggest that loss of 
lzap may alter intercellular adhesion, potentially contributing to abrogation of epiboly. 
Alternatively, intercellular spaces may be an early manifestation of LZAP-associated cellular 
defects that decrease cell survival. Together, these data suggest that LZAP may play a role in cell 
survival, proliferation, cleavage and/or cell adhesion, all of which may be required for epiboly. 
 
LZAP Is Required for Normal Cell Cycle, but Not Zygotic Gene Expression After MBT 
The MBT is marked by onset of zygotic gene expression with loss of synchronous cell division. 
To determine whether onset of zygotic transcription is disrupted by LZAP depletion, we 
examined several genes that initiate expression after MBT at 6 hpf. As expected, expression of 
zygotic genes bmp2b, eve1, and ntl/brachyury is initiated in zebraﬁsh embryos in blastomeres at 6 
hpf. In older, stage-matched mild lzap morphants, expression of these genes that mark onset of 
the MBT is indistinguishable from control embryos (Fig. 2.7A) (Joly et al., 1993; Schulte-Merker 
et al., 1994; Sidi et al., 2003; Ramel et al., 2005; Wilm and Solnica-Krezel, 2005). Anterior 
mesendoderm and hatching gland marker hgg1/cathepsin L expression is present in the polster of 
stage-matched mild morphants (Fig. 2.7A) (McFarland et al., 2005); however, the expression  
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Figure 2.7. Depletion of LZAP Causes Delay in Cell Cycle Progression but Does not 
Disrupt Zygotic Gene Expression after MBT 
(A)  The expression of bmp2b, eve1, ntl, and hgg1 in control and both age-matched and stage-
matched lzap morphant embryos were detected by whole-mount in situ hybridization. 
bmp2b expression, lateral view, 6 hpf in control. eve1 and ntl expression, top view, 6 hpf 
in control. hgg1 expression, lateral view, 12 hpf in control. 
(B)  Cell cycle analyses of dissociated zebrafish embryonic cells. DNA content was determine 
on untreated embryonic cells (a), on cells treated with 10 μg/ml nocodazole for 30 min 
(b), or on cells treated with nocodazole followed by release for 15 (c) or 30 min (d). Cells 
were assigned to G1, S, or G2/M based on fluorescent signal and manual gating using 
CellQuest Pro software. Results in the table represent the mean of at least three 
independent experiments. 
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domain is smaller as compared to controls. Collectively, these data suggest that the initiation of 
zygotic transcription is not disrupted by loss of LZAP. 
 
To investigate changes in cell cycle progression associated with LZAP loss, lzap morphant 
embryos were dissociated and cell cycle position of embryonic cells was determined by ﬂow 
cytometry after propidium iodide labeling at 4 hpf. As expected based on PCNA staining of early 
embryos (Fig. 2.5H), control and lzap morphant embryos are rapidly proliferating and primarily 
in S phase (51% vs. 53%). However, histograms of lzap morphant cells revealed a potential 
increase in G2/M and similar decrease in G1 populations relative to control (Fig. 2.7B-a). To 
better deﬁne the possible G2 delay, nocodazole was used to arrest cells in mitosis and cell cycle 
analyzed. In embryos treated with nocodazole for 30 min, G1 is similar between lzap morphants 
and controls, suggesting that loss of lzap does not impact progression through G1. As observed in 
untreated cells, lzap morphants treated with nocodazole have increased percentage of cells in 
G2/M (Fig. 2.7B-b). Embryos were released from nocodazole block to determine progression 
from mitosis into G1 and the remainder of the cell cycle. Cell cycle position of control cells 
following 15 minutes of release from nocodazole block reveal that they progress primarily to G1, 
whereas lzap morphant cells remain predominantly in G2/M (Fig. 2.7B-c). Following a 30-min 
release, control cells have progressed out of G1 into S and begin repopulating G2/M. In contrast, 
following 30 min release, lzap morphants are primarily in G1 and S, but have not begun to 
repopulate G2 (Fig. 2.7B-d). Although minor defects in G1 progression of cells derived from lzap 
morphants cannot be excluded, these data are most easily explained by a G2/M arrest associated 
with lzap loss. Analyses also reveal an increased sub-G1 population in lzap morphants consistent 
with increased apoptosis as observed by Caspase-3 staining (Fig. 2.5H). 
 
In parallel, we investigated spindle formation and chromosome alignment by 
immunoﬂuorescence at three consecutive stages (4h, 6h, 9h) past MBT. We labeled mitotic 
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spindles using α-tubulin antibody and condensed chromatin at metaphase and early anaphase by 
p-Histone H3 anti-body (Fig. 2.8A). We also analyzed overall size and shape of nuclei by TO-
PRO-3 labeling and confocal imaging of whole-mount preparations. We found that the nuclei are 
of comparable size and number at 4 hpf in morphants and controls, however, at 6 and 9 hpf the 
size and number of lzap morphant nuclei remain similar to the earlier stage while control nuclei 
increase in number and decrease in size (Fig. 2.8B). The formation of mitotic spindles is not 
disturbed by LZAP depletion, and chromosome alignment at metaphase is comparable between 
morphants and controls at all stages tested. Despite the distinction of nuclear size and number 
following LZAP loss, there are no gross abnormalities of chromatin morphology such as nuclear 
strings connecting nuclei or fragmented chromatin. These results suggest that LZAP depletion 
does not interfere with assembly of mitotic spindles and chromatin condensation or alignment 
during mitosis. 
 
Discussion 
The lzap gene structure and protein sequence are highly conserved across multicellular species, 
which may be a result of its critical developmental role. Here, we present a set of experiments 
that begin exploring the roles of LZAP during zebraﬁsh development. Given our observations of 
early embryonic death in lzap morphant zebrafish and in LZAP
-/-
 mice, findings related to LZAP 
role in early embryogenesis likely apply to other species as well. 
 
We show that LZAP is ubiquitously expressed during blastomere cleavage stages and gastrulation. 
Of interest, homozygous LZAP knockout mice are embryonic lethal, and LZAP
-/-
 embryos could 
not be found from dissection of pregnant females at or after embryonic day 4.5 (unpublished data). 
These results are consistent with the phenotype of the zebraﬁsh lzap morphant embryos that are 
lethal at a very early embryonic stage, before initiation of epiboly. Thus, both zebraﬁsh and 
murine data suggest that LZAP is essential for early embryogenesis. 
52 
 
  
Figure 2.8. Mitotic Spindles and Nuclear Morphology are not Disrupted in lzap 
Morphants 
(A)  Embryos with and without injection of 4 ng of lzap MO were co-immunostained with 
anti–α tubulin (red) and p-Histone H3 (green) antibodies at 4, 6, and 9 hpf in mitotic cells. 
Results are representative of observations from more than 100 nuclei for each panel. 
(B)  Confocal images of whole mount embryos with and without 4 ng lzap MO were stained 
with the nuclear marker TO-PRO-3. Pictures represent 4, 6, and 9 hpf. Scale bar: 40 μm. 
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We and others have shown that LZAP can bind to or regulate proteins involved in cell cycle 
progression (e.g., p53, ARF p38, Chk1/2, and CDK1) (Jiang et al., 2005, 2009; Wang et al., 
2006). Through these effectors, LZAP has been shown to regulate mitotic entry, G2/M 
checkpoint, cell cycle progression, and apoptosis. In zebraﬁsh development, we show that loss of 
lzap increases apoptosis and inhibits proliferation likely through inhibition of progression through 
G2 and M phases of the cell cycle. 
 
Epiboly 
Epiboly is the ﬁrst morphogenetic movement that in zebraﬁsh initiates approximately 1 hr after 
the MBT with intercalation of the deep blastomeres and animalward movement of the yolk 
(doming). Actin inhibitors and calcium chelators interrupt epiboly, but few genes have been 
implicated in this process (Cheng et al., 2004). In lzap morphants, despite progression through the 
MBT with expression of zygotic genes and mesodermal markers, neither doming nor epiboly was 
observed. Previously, four mutants were identiﬁed that arrest epiboly after it is initiated (Kane et 
al., 1996); however, genes corresponding to these mutants have not been assigned. Depletion of 
LZAP arrests epiboly before any morphogenetic movements begin suggesting that LZAP is not 
likely to be altered in these epiboly mutants. 
 
Zebraﬁsh mutants that disrupt development before the MBT have been isolated by mutagenesis 
strategies then selecting for maternal effect genes; however, most of the genes have yet to be 
cloned and none of the described mutants mimic the lzap morphant phenotype (Dosch et al., 2004; 
Abrams and Mullins, 2009). Pre-MBT mutants including irreducible (irr), indivisible (ini), 
atomos (aoo), cellular island (cei), and cellular atoll (cea) each failed to initiate cytokinesis, 
karyokinesis or both, whereas lzap morphants do not display abnormalities in cytokinesis or 
karyokinesis. The large cell morphology observed in lzap morphants is reminiscent of the 
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screeching halt (srh) mutant (Wagner et al., 2004). Similar to srh mutants, lzap morphants 
zygotically express ntl, eve1, and bmp2b, in a spatial pattern consistent with failure to progress 
past the sphere stage in age-matched embryos; however in stage-matched morphants, these genes 
are expressed in a normal pattern. Unlike srh, the lzap morphants present normal nuclear 
morphology, alignment of metaphase chromosomes, and mitotic spindle formation (Fig. 2.8A and 
B). 
 
The zebraﬁsh betty boop mutant (bbp) causes arrest of epiboly with constriction and bursting of 
the yolk cell at 50% epiboly. This defect was linked to an inactivating mutation of MAPKAPK2 
(Holloway et al., 2009). MAPKAPK2 is a downstream target of the mitogen activated protein 
kinase p38 and dominant-negative mutations of p38MAPK recapitulate the bbp phenotype. 
Likewise, mutations in the homeobox transcription factor, Mxtx2, result in a similar 
phenotype (Bruce et al., 2005; Wilkins et al., 2008). Although yolk bursting was not observed in 
lzap morphants, we have recently found that human LZAP binds and inhibits p38MAPK 
suggesting that this pathway could be involved in epiboly defects observed in LZAP depleted 
animals (An et al., 2011). 
 
Cell Cycle 
In mammalian cells loss of LZAP results in cell cycle defects. To determine whether cell cycle 
progression is altered in lzap morphants, proliferative and mitotic indices and cell cycle position 
are determined in cells dissociated from early embryo (Fig. 2.5). Percentages of proliferating and 
mitotic cells are decreased in lzap morphant embryos. Flow cytometric analyses suggested that 
fewer cells from lzap morphants are in G1 and more cells are in G2/M compared to untreated or 
control embryos, but analyses of unperturbed cells is limited because of the rapid cell cycle at this 
stage with the majority of cells positioned in S phase (Zamir et al., 1997). Nocodazole treatment 
and release was used to more ﬁnely determine cell cycle effects of LZAP loss (Fig. 2.7B). 
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Following removal of nocodazole, lzap morphants are delayed in exit from the G2/M phase, 
suggesting that LZAP loss in embryonic cells results in a G2/M delay. Polo-like kinase 1 (Plk1) 
and SCL-interrupting locus (SIL) are required for progression through mitosis and result in 
embryonic growth defects (Pfaff et al., 2007; Jeong et al., 2010). Both Plk1 and SIL result in 
disorganized mitotic spindles as opposed to lzap morphants whose spindles are morphologically 
normal (Fig. 2.8A). 
 
LZAP loss in mammalian cells delays mitotic entry through activation of Chk1 and Chk2 
consistent with our ﬁndings in unsynchronized cells. However, nocodazole results in a mitotic or 
spindle checkpoint arrest triggered by unattached kinetochores (Amon, 1999; Musacchio and 
Hardwick, 2002). Results presented here suggest that in addition to delaying exit from the G2 
checkpoint, LZAP may also regulate exit from the spindle checkpoint. 
 
Apoptosis 
Of interest, non-mammalian vertebrate embryos do not manifest spontaneous apoptosis before 
gastrulation; however, apoptotic machinery is present and apoptosis can be induced in zebraﬁsh 
embryos post MBT by inhibition of protein synthesis or DNA replication (Ikegami et al., 1999; 
Negron and Lockshin, 2004). Mutation of grp and Mei in ﬂies results in embryonic death, but 
apoptosis in these embryos has not been evaluated (Sibon et al., 1997, 1999). Likewise, apoptosis 
is not examined in screeching halt zebraﬁsh mutants (Wagner et al., 2004). Here, we show that 
lzap morphant embryos have a signiﬁcant proportion of cellular apoptosis as early as 6 hpf (Fig. 
2.5H, 2.5K, 2.6B and 2.6C). Despite the ability of LZAP to activate p53 and p53’s accepted role 
as an inducer of cell cycle arrest and apoptosis, concomitant loss of p53 does not affect severity 
of the lzap MO phenotype nor rescue lzap morphants. Gaps between cells were commonly 
observed in 6 hpf lzap morphant embryos, less frequently observed in rescued morphants and not 
observed in control embryos. The mechanism responsible for loss of cell–cell adhesion has not 
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been explored, but could relate to loss of adhesion molecules or may simply be a marker of 
impending cell death. 
 
Combined, our data suggest that LZAP function is critical for normal progression through the 
G2/M of the cell cycle and to prevent apoptosis in early embryos. LZAP also appears to be 
required for initiation of epiboly. Inhibition of doming and epiboly in lzap morphants is exciting 
and suggest that lzap activity is required at or before the earliest stages of cellular and tissue 
differentiation at a stage that all cells maintain stem cell characteristics. The absence of initiation 
of doming or epiboly in lzap morphants is even more remarkable given that E-cadherin mutants 
with disrupted cell–cell adhesion still are capable of doming (Kane et al., 2005; Shimizu et al., 
2005). LZAP-deﬁcient zebraﬁsh embryos show disrupted development at an earlier time point 
than ﬁsh with mutated E-cadherin, MAPKAPK2, or p38MAPK or than in described epiboly 
mutants and at a stage where embryonic cells should maintain a pluripotency (Ma et al., 2001). 
These studies suggest that LZAP may be required for embryonic stem cell maintenance or 
appropriate cell fate determination. 
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CHAPTER III 
 
LOSS OF LZAP REPRESENTS A NEW MECHANISM OF P53 INACTIVATION 
IN HUMAN CANCER 
 
The work presented in this chapter has been submitted to the Journal of Clinical Investigation. 
 
Summary 
We reported that LZAP has tumor suppressor activity, is lost in a portion of HNSCC and inhibits 
NF-κB. Here, we show that LZAP downregulation diminishes mutant and wild-type p53 protein 
expression, even after genotoxic stress. Loss of LZAP decreases p53 translation and destabilizes 
p53, at least partially due to increased expression of nucleolin (NCL). Importantly, knockdown of 
LZAP abrogates p53 stabilization induced by ionizing radiation, and downregulation of LZAP 
protects wild-type p53 cells from radiation while sensitizing cells expressing mutant or no p53. 
The importance of LZAP loss in tumorigenesis is suggested by correlation of LZAP and p53 
levels in HNSCC tumors and by the decreased frequency of p53 mutations found in HNSCCs 
with low LZAP expression. These data suggest that loss of LZAP represents a novel mechanism 
of p53 inactivation in human cancer. 
 
Significance  
Our findings suggest that loss of LZAP represents a new mechanism of p53 inactivation in human 
cancers. Regardless of p53 mutational status, LZAP depletion downregulates p53 at multiple 
levels, even after genotoxic stress. In addition, loss of LZAP mitigates the need for p53 mutation 
in human tumors. LZAP regulation of p53 is, at least partially, dependent on NCL and LZAP 
regulates NCL protein levels. Disruption of LZAP activity toward p53 may present a promising 
therapeutic opportunity, since LZAP depletion decreases levels of both wild-type and mutant p53, 
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with protection of wild-type, but sensitization of mutant p53 cells to radiation-, or chemotherapy-
induced death. Therefore, temporary inhibition of LZAP activity toward p53 for patients with 
tumors harboring p53 mutations may simultaneously sensitize the tumor and protect normal 
surrounding tissues from radiation damage. 
 
Introduction  
HNSCC accounts for more than 90% of all head and neck cancers and is the sixth most common 
cancer worldwide, affecting approximately 50,000 people in the United States annually (Siegel et 
al., 2012). Recently, we reported that expression of LZAP (also known as Cdk5rap3 and C53) 
protein is decreased in approximately 30% of HNSCC (Wang et al., 2007b), and that LZAP loss 
is associated with increased anchorage independent growth, cellular invasion, and xenograft 
tumor growth, suggesting that LZAP has tumor suppressor activity. LZAP has also been proposed 
as a candidate tumor suppressor in hepatocellular carcinoma, where low LZAP expression was 
found to be independently associated with poor prognosis, and expression of LZAP in HCC cell 
lines triggered apoptosis and inhibited both proliferation and xenograft tumor growth (Zhao et al., 
2011). Conversely, LZAP expression in hepatocellular carcinoma has been associated with poor 
prognosis, invasiveness, and metastases (Mak et al., 2011, 2012), with grade and depth of 
invasion in colon adenocarcinoma (Chen et al., 2011), and LZAP is frequently overexpressed in 
lung adenocarcinoma (Stav et al., 2007). We and others have described LZAP activity toward 
ARF (Wang et al., 2006), p38 (An et al., 2011), RelA subunit of NF-κB (Wang et al., 2007b), 
Chk1 and Chk2 (Jiang et al., 2009), Wip1 (unpublished data). As we have shown, LZAP activates 
p53 through both ARF-dependent and ARF-independent pathways (Wang et al., 2006); however, 
detailed mechanisms of LZAP functions, particularly ARF-independent LZAP effects on p53, 
remain unclear. 
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p53 is universally or nearly-universally inactivated in human cancers through a variety of 
mechanisms. p53 is inactivated directly by mutation, or indirectly through binding to viral 
proteins or as a result of alterations in genes, whose products either activate, stabilize, or carry 
signals from p53 (Hupp et al., 2000; Vogelstein et al., 2000; Lane and Lain, 2002; Lane and Hupp, 
2003). As a protein directing critical cellular processes and a potent inductor of apoptosis, p53 
expression is tightly controlled, and the number of p53 regulators continues to increase. 
 
NCL was recently described as a regulator of p53 with activity to alter p53 expression at several 
levels. First, following DNA damage, NCL was found to bind the 5’ UTR of p53 mRNA and 
suppress p53 translation, and under similar conditions, downregulation of NCL was found to 
increase p53 protein expression (Takagi et al., 2005). Second, NCL has been reported to 
destabilize p53 and diminish its activity; however, studies in this area are conflicting, suggesting 
that depletion of NCL increases p53 protein stability and activity (Yang et al., 2011). Opposingly, 
NCL, like ARF, has been shown to stabilizes p53 by binding and inhibiting Hdm2 (Saxena et al., 
2006). NCL is an extraordinary functionally pleiotropic protein with intrinsic DNA and RNA 
helicase, nucleic-acid-dependent ATPase and self-cleaving activities that is found in multiple cell 
compartments, including nucleoli, nucleoplasm, cytoplasm and cell surface (Mongelard and 
Bouvet, 2007; Tajrishi et al., 2011). NCL functions in transcription and translation, chromatin 
remodeling, viral infection, and at several steps of DNA and RNA metabolism; however, detailed 
molecular mechanisms of these activities are not fully understood. Although NCL is upregulated 
in cancer, autoimmune syndromes, Alzheimer’s and Parkinson’s diseases, as well as other 
pathological conditions, very little is known about regulation of its levels or activities. 
 
Current anticancer therapies, including those used to treat head and neck cancer, are associated 
with severe side effects limiting dose and efficacy. Because these side effects occurring in normal 
tissues are, at least in part, dependent on the p53-mediated apoptosis, transient downregulation or 
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suppression of p53 has been explored as a therapeutic strategy to protect normal cells during 
cancer treatment (Komarov et al., 1999; Botchkarev et al., 2000; Gudkov and Komarova, 2003, 
2005; Leonova et al., 2010). Mutations in the TP53 gene occur in around 50% of human tumors 
including HNSCC and are associated with rapid tumor progression and resistance to anticancer 
therapy also (Koch et al., 1996; Poeta et al., 2007; Skinner et al., 2012). Emerging data firmly 
support a gain-of-function roles for mutant p53, suggesting that targeting of mutant p53 may be a 
promising anticancer treatment strategy (Oren and Rotter, 2010; Rivlin et al., 2011; Blandino et 
al., 2012). Much effort has been directed to restoring wild-type p53 function in tumor cells 
expressing mutant p53 (Selivanova et al., 1998; Foster, 1999; Bykov et al., 2002, 2003; 
Selivanova and Wiman, 2007); however, the strategy of inhibiting both mutant (in cancer cells) 
and wild-type p53 (in normal surrounding cells) has not been well studied. Transient inhibition of 
wild-type and mutant p53 with simultaneous sensitization of mutant p53 cancer cells and 
protection of normal tissues from severe side effects may be useful in combination with radio- 
and chemo-therapy to target p53 mutant cancers. 
 
Here, we show that depletion of LZAP increases NCL expression and decreases expression of 
p53, regardless of p53 mutation status or the presence or absence of genotoxic stress. Loss of 
LZAP alters p53 expression through inhibition of translation and decreased p53 protein stability. 
LZAP activity toward p53 is independent of ARF, Wip1, and HDM2, all of which are known p53 
regulators. In human HNSCC, LZAP and p53 protein levels linearly correlate, and tumors 
expressing low levels of LZAP have a significantly lower TP53 mutation incidence compared to 
tumors with high LZAP. Together, these data suggest that loss of LZAP represents a new 
pathway for p53 inactivation in human cancer. Depletion of LZAP in cancer cells expressing 
wtp53 protects them from DNA damage-induced cell death, and loss of even one LZAP allele in 
normal bone marrow cells derived from LZAP heterozygous mice increases cells resistance to 
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radiation. In contrast, cells expressing mutant or no p53 are sensitized to radiation and 
chemotherapeutic drugs treatment upon loss of LZAP. 
 
Methods 
Cell Lines, Transfection and Lentiviral Infection 
U2OS and Saos-2 human osteosarcoma cells, HCT116 p53
+/+
 and p53
-/-
 colorectal carcinoma 
cells, JHU012, FaDu and SCC-61 HNSCC cells were cultured in complete growth medium 
suggested by American Type Culture Collection (ATCC) at 37ºC under 5% CO2. Wild-type, 
Wip1
-/-
 and p53
-/-
/Mdm2
-/-
 MEFs were cultured at 37ºC under 5% CO2 in hypoxia (2% O2). 
 
The U2OS Tet-on cell line was generated following BLOCK-iT Inducible H1 RNAi Kit 
(Invitrogen) protocol. GenMute transfection reagent (SignaGen) was used for siRNA and plasmid 
transfection. LZAP, NCL and control (ON-TARGETplus Non-targeting) siRNAs were from 
Dharmacon. For shRNA-mediated knockdown GIPZ lentiviral shRNA (control non-silencing and 
human LZAP shRNA) vectors were purchased from Thermo. All cell lines used were confirmed 
as unique and, where possible, matched to microsatellite profiles using the Cell ID kit from 
Promega. 
 
p53 luciferase reporters were kind gift from J.A. Pietenpol. GFP-p53 expressing vectors were a 
gift from G. Selivanova. 
 
Creation of LZAP heterozygous mice 
LZAP was targeted in murine embryonic stem cells by homologous recombination using a LZAP 
floxed construct targeting the first 2 exons of murine LZAP. After selection, clones were screened 
by PCR and Southern blotting with 2 independent recombinant clones (2A2 and 2G5) identified. 
Mice were crossed with B6.FVB-Tg(EIIa-cre)C5379Lmgd/J mice (Jackson Laboratories) and 
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then crossed for 6 generations with C57Bl/6 mice (Jackson Laboratories). Genotype of LZAP 
mice was confirmed by PCR using primers: 5’-TGTGCCACCACGCAACTTTT-3’ and 5’-
CATGAAGACAGAACCAAAC-3’. 
 
BM-MNCs Colony Forming Assay 
C57Bl/6 wild-type and LZAP heterozygous mice were treated with total body irradiation (6 Gy) 
or left untreated (four mice in each group). 4 hr after TBI, BM-MNCs were isolated from femurs 
and tibias of each mouse and plated (4 x 104 cells/ml in 35 mm diameter plates) in MethoCult 
M3231 medium (StemCell Technologies) supplemented with 10 ng/ml recombinant mouse GM-
CSF (StemCell Technologies) and IMDM growth medium (Invitrogen). Colony formation (MEP 
and GMP) was scored after 7 days of culture at 37°C in the presence of 5% CO2. MEP and GMP 
colonies were distinguished based on morphology (condensed MEP and dispersed GMP). 
 
Gene Expression 
Total RNA was extracted from the cells using RNeasy Mini Kit (QIAGEN) and reverse-
transcribed into cDNA (Bio-Rad). SYBR green (Bio-Rad) real-time quantitative PCR was 
performed using a CFX96 Real-Time System (Bio-Rad). The following sets of primers were used: 
lzap (5’-CAATGCTGCCATCCAGGACATG-3’ and 5’-ATCCGCTGTGAAGAGTATCGGC-
3’), p53 (5’-CCTCAGCATCTTATCCGAGTGG-3’ and 5’-
TGGATGGTGGTACAGTCAGAGC-3’), and β-actin (5’-CACCATTGGCAATGAGCGGTTC-3’ 
and 5’-AGGTCTTTGCGGATGTCCACGT-3’). The expression of mRNA of interest was 
normalized to the expression of β-actin. 
 
RT
2
 Profiler PCR Array (Human p53 Signaling Pathway) was performed according to the 
manufacturer’s instructions and analyzed using the vendor’s online software (QIAGEN). 
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DNA Purification and p53 Sequencing 
Twenty-nine human HNSCC tumor specimens were obtained from formalin-fixed and paraffin-
embedded slides. DNA was extracted using Recover All Total Nucleic Acid Isolation Kit (FFPE) 
(Ambion). Exons 4-10 of human p53 gene were amplified and sequenced according to the 
protocol from International Agency for Research on Cancer (IARC). 
 
Immunoprecipitation and Immunoblotting 
Cells were lysed in RIPA lysis buffer (Sigma) with proteinase inhibitor cocktail (Roche) and 
phosphatase inhibitors (Sigma), protein concentration was measured with Bradford protein assay 
(Bio-Rad). For immunoprecipitation, 1 mg of whole cell extracts was incubated with 2 μg of p53, 
LZAP or NCL antibodies or rabbit IgG, overnight at 4ºC. 30 μl of slurry of Protein A/G-agarose 
beads (Santa Cruz) was then added and incubated for 1-2 hrs. Immunocomplexes were 
centrifuged, washed four times with ice-cold lysis buffer, incubated 10 min. at 70°C, centrifuged, 
separated in NuPAGE 4-12% Bis-Tris Mini Gel (Invitrogen) and transferred to Immobilon PVDF 
Membranes (Millipore). Immunoblots were incubated with primary antibodies overnight at 4ºC 
followed by fluorescent secondary IRDye 680LT anti-mouse IgG and IRDye 800CW anti-rabbit 
IgG (LiCore) for 1 hr. Signals were detected by infrared fluorescence (Odyssey). 
 
The following primary antibodies were purchased from Santa Cruz Biotechnology: mouse 
monoclonal anti-LZAP (ZZ-7), mouse monoclonal anti-NCL (MS-3), rabbit polyclonal anti-NCL 
(H-250), mouse monoclonal anti-p21 (F-5), mouse monoclonal p53 (DO-1), rabbit polyclonal 
anti-p53 (FL-393), rabbit polyclonal anti-GAPDH (FL-335), mouse monoclonal anti-β-actin (C-
4). Mouse monoclonal anti-MDM2 (2A10) was obtained from Abcam; rabbit polyclonal anti- 
phospho-p53 (Ser15) was from Cell Signaling; rabbit polyclonal anti-LZAP antibody serum was 
produced as described (Wang et al., 2007b); rabbit polyclonal anti-LZAP (HPA022141) for IHC 
staining was obtained from Sigma.  
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p53 Protein Stability 
Cells were treated with 25 μM cycloheximide (Sigma) and collected at indicated time points. 
Immunoblotting was performed with LZAP and p53 antibodies. 
 
In vivo 
35
S-protein Labeling 
Cells were transfected with control or LZAP siRNAs; 48h after transfection, culture medium was 
changed to methionine/cysteine-free medium supplemented with EasyTag Express Protein 
Labeling Mix (PerkinElmer) and cells were incubated for 10 min. Protein extracts were 
immunoprecipitated with p53 antibody and a newly synthesized p53 protein was analyzed by 
SDS-PAGE and autoradiography as previously described. SDS-PAGE of whole cell protein 
extracts followed by autoradiography was used to estimate global rate of translation. 
 
Immunohistochemistry 
Specimens were fixed with 10% formalin and embedded in paraffin per routine of the surgical 
pathology division. Sectioning and immunostaining were performed by the Vanderbilt 
Translational Pathology Shared Resource using antibodies: LZAP (HPA022141, Sigma) and p53 
(DO1, Santa Cruz Biotechnology). 
 
Clonogenic Survival Assay 
Clonogenic survival assay was performed as we described before (Gubanova et al., 2012). All 
experiments were performed in triplicate. 
 
Cell Viability Assay 
Cells viability assays were performed using WST-1 cell proliferation reagent (Roche) according 
to the manufacturer’s instructions. All experiments were performed in triplicate. 
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Human Tumor Tissue 
Tumors used for this study were obtained from biopsy or surgical specimens after patient consent 
and after IRB approval. Prior to lysis for immunoblotting, tumor content was enriched to >75% of 
total cellular content by macrodissection of frozen sections. 
 
Statistical Analysis 
Results are reported as mean ± SEM of three independent experiments. Comparisons were 
performed by using GraphPad Prism S software unless specifically noted. 
 
Results 
LZAP Loss Decreases p53 Protein Levels Regardless of p53 Mutation Status 
Targeting of a single LZAP allele by homologous recombination in murine ES cells revealed 
lower LZAP expression in 2 of 2 independently derived clones (~40% 2A2 and 60% 2G5) 
(Fig.3.1A). We were surprised that p53 protein levels were similarly decreased in ES cell clones 
after targeting of LZAP (~40% 2A2, and 50% 2G5) (Fig. 3.1A). To determine if LZAP depletion 
similarly regulated p53 levels in human cells, two different LZAP siRNAs were transfected into 
human cancer cell lines carrying wild-type p53 (wtp53) (U2OS - human osteosarcoma, JHU012 
and SCC61 - both human HNSCC). Downregulation of LZAP was associated with markedly 
decreased p53 protein in all lines tested (Fig. 3.1B). These findings were confirmed using U2OS 
cells stably expressing an LZAP shRNA under control of tetracycline-inducible promoter (Tet-
on), where addition of doxycycline resulted in a dose-dependent decrease in LZAP expression 
that is paralleled by decreased p53 protein levels (Fig. 3.1C). 
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Since loss of LZAP was associated with marked downregulation of wtp53, effects of LZAP 
depletion on mutant p53 (mtp53) protein level was explored. p53 null osteosarcoma Saos-2 cells 
were co-transfected with control or LZAP siRNAs and two different ―hot spot‖ p53 mutants  
  
Figure 3.1. LZAP Loss Results in Downregulation of Both Wild-type and Mutant p53 
(A)  Immunoblot detecting LZAP and p53 in parental ES cells (wild-type) and in ES cell 
clones (2A2 & 2G5) after homologous recombination targeting LZAP. Immunoblotting of 
GAPDH serves as loading control. 
(B)  Immunoblot detecting LZAP and p53 proteins in wtp53 cell lines transfected with control 
or siRNAs specific to LZAP. Immunoblotting of b-actin serves as loading control. 
(C)  Left: Immunoblot detecting LZAP and p53 proteins in U2OS cells with doxycycline-
regulated (Tet-on) knockdown of LZAP; right: Quantification of LZAP and p53 levels 
normalized to β-actin. 
(D)  Immunoblot detecting LZAP and ectopically expressed mutant p53 (R175H and R248Q) 
in p53 null Saos-2 cells with and without LZAP knockdown. 
(E) Immunoblot detecting LZAP and endogenous mutant p53 in SCC-25 cells with and 
without LZAP knockdown. 
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(R175H and R248Q) or vector as control. Consistent with findings from cells expressing wtp53, 
depletion of LZAP downregulated mtp53 proteins in cells ectopically expressing mutant p53 (Fig. 
3.1D). These data suggest that LZAP loss downregulates p53 protein levels irrespective of p53 
mutation status. 
 
LZAP Loss Inhibits Wild-type p53 Transactivation, Rendering Wild-type p53 Expressing Cells 
Resistant to Radiation and Chemotherapeutic Drugs 
p53 is a primary regulator of cellular response to standard anticancer therapies (e.g. radiation and 
cytotoxic chemotherapy) (Komarova and Gudkov, 2000; Gudkov and Komarova, 2005, 2007); 
therefore, transient downregulation or suppression of wtp53 function has been proposed and 
experimentally confirmed as a strategy to protect normal cells from consequences of radiation or 
chemotherapy (Komarova and Gudkov, 1998, 2001; Gudkov and Komarova, 2003, 2005). 
  
Since LZAP depletion downregulated p53 (Fig. 3.1), we suspected that LZAP depletion could 
also protect cells expressing wtp53 from radiation or chemotherapeutic drugs. To determine if 
biological consequences of LZAP deficiency were dependent on p53 status, isogenic HCT116 
cell lines (human colon cancer) with and without p53 (HCT116 p53
+/+
 and HCT116 p53
-/-
, 
respectively) were infected with control lentivirus or lentivirus driving expression of LZAP 
shRNA. Cells were plated for clonogenic survival and treated with increasing doses of gamma 
irradiation. Depletion of LZAP in HCT116 p53
+/+
 cells rendered them more resistant to radiation 
(Fig. 3.2A and B). In contrast, depletion of LZAP in cells lacking p53 (HCT116 p53
-/-
) enhanced 
their sensitivity to identical radiation doses (Fig. 3.2A and B). 
 
Limiting p53 activity improves survival of cells following radiation, an effect largely attributed to 
reduced induction of apoptosis. To determine if LZAP depletion could reduce induction of 
apoptosis following DNA damage, LZAP was depleted in HCT116 p53
+/+
 cells before exposure  
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Figure 3.2. LZAP Depletion Protects p53 Wild-type Cells from Radiation but Sensitizes 
p53 Null Cells to Radiation 
(A) Left: Clonogenic survival of isogenic cell lines, HCT116 p53
+/+
 and HCT116 p53
-/-
, after 
radiation with indicated doses with and without LZAP knockdown. Middle: 
Representative plates following treatment with 5 Gy showing stained colony at the end of 
experiment. Right: Immunoblot confirming LZAP downregulation upon shRNAs 
expression. 
(B) Histograms showing annexin V staining in control and LZAP knockdown HCT116 p53
+/+
 
cells with and without Zeocin treatment. The percentage of cells with increased annexin V 
staining after zeocin treatment was determined in control and LZAP knockdown cells and 
is presented beneath the histograms.  
(C) U2OS cells were infected with lentiviral construct expressing empty vector or shLZAP 
and plated for clonogenic survival. p53 inhibitors PFT-α were added 1 h before exposure 
to increasing doses of IR. Colonies were stained and counted. 
(D) U2OS cells were infected with lentiviral construct expressing empty vector or shLZAP 
and plated for clonogenic survival. p53 inhibitors PFT-μ were added 1 h before exposure 
to increasing doses of IR. Colonies were stained and counted. 
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to the radiomimetic drug zeocin and apoptotic cells were measured by annexin V staining. 
Compared to control cells, LZAP knockdown reduced the percentage of apoptotic cells following 
Zeocin treatment by approximately 4-fold (19% vs. 5%) (Fig. 3.2B). 
 
In response to DNA damage, p53 initiates apoptosis through both transcriptional transactivation 
of specific pro-apoptotic target genes and through a transcription-independent mechanism, 
involving translocation of p53 to mitochondria. To begin distinguishing which p53 functions are 
impacted by LZAP loss, small molecular inhibitors of p53, pifithrin-α (PFTα), an inhibitor of p53 
transactivation function, and pifithrin-µ (PFTµ), an inhibitor of p53 mitochondrial 
translocalization, were employed (Komarov et al., 1999; Strom et al., 2006). As expected, LZAP 
depletion alone or treatment of HCT116 p53
+/+
 cells with either p53 inhibitor singly protected 
cells from radiation (Fig. 3.2C and D). In addition to radioprotection afforded by PFTµ, depletion 
of LZAP further improved survival of HCT116 p53
+/+
 cells following radiation (Fig. 3.2C). In 
contrast, LZAP depletion did not improve survival of HCT116 p53
+/+
 more than treatment with 
PFTα alone following radiation (Fig. 3.2D). These data suggest that radioprotection following 
LZAP downregulation likely functions primarily through regulation of p53 transactivation 
activity. 
 
Stress responsive kinases, ATM and ATR, are rapidly activated after DNA damage and 
phosphorylate p53 protein at different sites, including Ser15, leading to the disruption of the 
interaction between p53 and MDM2 with resultant p53 stabilization and activation. Depletion of 
LZAP by siRNAs reduced levels of Ser15 phosphorylated p53 and total p53 in untreated cells and 
at several time points following treatment with 5 Gy irradiation (Fig. 3.3A). Despite the overall 
lower levels of p53 and phospho-Ser15 p53, the timing of p53 induction and p53 phosphorylation 
at Ser15 after radiation was not altered by LZAP loss, suggesting that LZAP depletion did not 
affect radiation induction of kinases, but rather decreased initial and stimulated p53 levels. 
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Figure 3.3. LZAP Depletion Inhibits p53 Transcriptional Transactivation 
(A) Immunoblot detecting LZAP, total p53 and p(S15)p53 levels in U2OS cells transfected 
with control or LZAP siRNAs and collected at the indicated time points after 5 Gy 
radiation. 
(B) p53-dependent luciferase activity was determined using the p53 responsive luciferase 
construct (PG13-Luc) in HCT116 p53
+/+
 cells at basal state and 4 hours after 5 Gy IR with 
or without siRNA-mediated depletion of LZAP. HCT116p53
-/-
 cells, as well as a mutant 
luciferase construct not responsive to p53 (MG15-Luc) served as controls. 
(C) U2OS cells were transfected with LZAP or control siRNAs. Expression of several p53 
responsive genes was determined by p53 Signaling Pathway PCR array in untreated cells 
or 4 hr after irradiation (5Gy). 
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To more directly measure the effect of LZAP loss on p53 transactivation, luciferase reporters, 
containing either p53 responsive elements (PG13-Luc) or mutated p53 responsive elements 
(MG15-Luc), were transfected into HCT116 p53
+/+
 cells and LZAP levels manipulated by co-
transfection with siRNAs. Consistent with findings that depletion of LZAP downregulated p53 
and abolished p53 stabilization and phosphorylation after radiation (Fig. 3.3A), LZAP loss 
diminished p53 transcriptional transactivation activity by approximately 50% in both unstressed 
and radiated HCT116 p53
+/+
 cells compared to cells transected with control siRNAs (Fig. 3.3B). 
LZAP loss did not affect the minimal luciferase activity detected following transfection of 
HCT116 p53
-/-
 cells with p53-reponsive luciferase reporter or transfection of HCT116 p53
+/+
 or 
p53
-/-
 cells with a luciferase construct containing mutated p53 responsive elements (Fig. 3.3B). To 
determine if decreased p53 transactivation observed upon LZAP loss affected expression of 
known p53 target genes, the Human p53 Signaling Pathway PCR array (Qiagen) was used to 
determine relative mRNA levels of several genes in U2OS cells with and without radiation. 
Expression of p21, MDM2, BTG2, BAX, BID, PIDD, APAF-1 and MDM4 were diminished in 
cells following LZAP depletion at basal levels and following p53 activation by 4 Gy irradiation 
(Fig. 3.3C). While depletion of LZAP effectively decreased induction of each p53 target gene 
following radiation, it was remarkable that loss of LZAP completely inhibited radiation-induced 
expression of BID, PIDD, APAF1 and MDM4 above basal levels. 
 
LZAP loss sensitized p53
-/-
 cells and protected p53
+/+
 cells following radiation treatment (Fig. 
3.2A). To determine if biological consequences of LZAP depletion seen after radiation extended 
to chemotherapeutic agents having distinct mechanisms of action, cell viability assays were 
performed following treatment with carboplatin (DNA/DNA and DNA/protein crosslinker), 
doxorubicin (DNA intercalating agent), and paclitaxel (microtubule stabilizer and anti-mitotic). 
Regardless of the mechanism of action, loss of LZAP protected HCT116 p53
+/+
 cells and 
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sensitized isogenic HCT116 p53
-/- 
cells to chemotherapeutic drugs (Fig. 3.4A). Increased 
sensitivity to these drugs was also observed following LZAP depletion in a human osteosarcoma 
cells lacking p53 expression (Saos-2) while resistance was observed in similarly treated human 
osteosarcoma cells that express wtp53 (U2OS) (Fig. 3.4B). 
 
Loss of a Single lzap Allele Protects Murine Bone Marrow Cells from Radiation-induced Cell 
Death 
Depletion of LZAP in cancer cells expressing wtp53 protected them from radiation- or 
chemotherapy-induced cell death (Fig. 3.2, 3.3 and 3.4); however potential clinical relevance 
relies on determining the effect of LZAP loss on normal, non-cancer cells. Bone marrow 
mononuclear cells are exquisitely sensitive to radiation through mechanisms largely attributed to 
p53-associated apoptosis. Bone marrow sensitivity is the major cause of organismal demise 
following whole body irradiation and is the major dose-limiting factor for many chemotherapy 
regimens. Acute bone marrow suppression occurs following total body irradiation; however, p53 
inhibition mitigates this syndrome (Komarov et al., 1999; Strom et al., 2006). To begin exploring 
the effect of LZAP loss on normal cell survival after radiation, wild-type (LZAP
+/+
) and LZAP 
heterozygous (LZAP
+/-
) mice were irradiated with sublethal doses of total body irradiation (TBI) 
and clonogenic growth of isolated bone marrow mononuclear cells (BM-MNC) was determined. 
Mice with homozygous loss of LZAP are not available for study because of early embryonic 
lethality (less than E4.5 days) as also confirmed in a zebrafish model (Liu et al., 2011). In 
agreement with observations that p53 was downregulated following LZAP targeting in murine ES 
cells (Fig. 3.1A), p53 levels in bone marrow cells derived from LZAP
+/-
 mice were lower 
compared to levels in bone marrow cells from LZAP
+/+
 mice (Fig. 3.5A). Remarkably, 
upregulation of p53 expression after radiation was dampened in LZAP
+/-
 bone marrow cells 
compared to wild-type cells (Fig. 3.5A). Radiation did not appreciably alter LZAP levels in either 
wild-type or LZAP heterozygous bone marrow cells (Fig. 3.5A). To determine if cell survival and  
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Figure 3.4. LZAP Depletion Alters Cellular Sensitivity to Chemotherapeutic Agents in a 
p53-dependent Manner 
Cell proliferation with and without LZAP knockdown was determined by WST-1 analyses 
following treatment with the indicated concentration of carboplatin, doxorubicin, and 
paclitaxel in HCT116 p53+/+ and -/- cells (A) and Saos-2 (p53 null) and U2OS (wtp53) cells 
(B). 
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  Figure 3.5. Loss of a Single lzap Allele Protects Murine Bone Marrow Cells from IR 
(A) Immunoblot detecting LZAP and p53 in bone marrow cells derived from LZAP
+/+
 and 
LZAP
+/-
 mice before and 4 hr after 6 Gy total body irradiation. Immunoblotting of β-actin 
serves as loading control. 
(B) Survival and proliferation of bone marrow progenitor cells derived from untreated wild-
type or LZAP
+/-
 mice or littermates treated with 6Gy TBI was determined after 7 days of 
in vitro growth. Granulocyte-macrophage progenitors (GMP) and megakaryocyte-
erythroid progenitors (MEP) colonies were identified by colony morphology. Data are 
presented as mean ± SD (n=4 mice each group). 
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proliferative capacity differed between BM-MNC derived from wild-type and LZAP
+/-
 mice, BM-
MNCs were isolated either after no treatment or 4 hr after total body irradiation. Irradiation 
decreased colony forming capacity in cells derived from both wild-type and LZAP
+/-
 mice; 
however, bone marrow progenitor cells derived from LZAP
+/-
 mice of both 
granulocyte/macrophage (GMP) and megakaryocyte/erythroid (MEP) lineages were significantly 
protected compared to cells derived from wild-type mice (Fig. 3.5B). These data are consistent 
with radio- and chemotherapy resistance following LZAP depletion observed in cancer cells 
expressing wtp53, and suggest that lower LZAP expression driven by loss of a single lzap allele 
in LZAP heterozygous mice is sufficient to render bone marrow mono-nuclear cells more 
resistant to radiation (Fig. 3.5). 
 
Together, these data suggest that LZAP loss decreases wtp53 levels and inhibits p53 
transcriptional transactivation resulting in protection of both cancer and non-cancer wtp53 
expressing cells from p53-mediated cell death following exposure to radiation or 
chemotherapeutic agents. 
 
LZAP Loss Sensitizes Cells Expressing Mutant p53 to Radiation  
LZAP depletion correlated with decreased mtp53 protein levels (Fig 3.1D). As opposed to the 
pro-apoptotic effects of wtp53 in response to therapy, mutations in the TP53 gene frequently have 
gain-of-function activity that increases cancer cell therapeutic resistance. Because normal cells 
will not express mutant p53, inhibition of gain-of-function p53 mutants is an attractive target for 
anticancer therapy, particularly in combination with radiation and chemotherapy (Oren and Rotter, 
2010; Goldstein et al., 2011). 
 
To determine if downregulation of mutant p53 levels following LZAP loss sensitizes cells to 
radiation, cells were radiated after siRNA-mediated LZAP depletion in p53-null Saos-2 cells 
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ectopically expressing two different p53 ―hot spot‖ mutants (R175H and R248Q). Clonogenic 
survival revealed that cells expressing mtp53 were sensitized to radiation upon loss of LZAP 
(both R175H and R248Q) (Fig. 3.6).  
  
p53 Downregulation in LZAP Depleted Cells is Not Mediated Through ARF, MDM2, or Wip1 
To begin exploring potential mechanisms through which LZAP regulates p53 protein levels, 
dependence on known LZAP binding partners and p53 regulators was tested. We reported that 
LZAP activates p53 through binding to ARF (Wang et al., 2006); however, neither U2OS nor 
HCT116 cells express ARF, indicating that ARF is not required for LZAP regulation of p53 
levels. 
 
Recently, we reported that LZAP binds and regulates the activity of the wild-type p53-induced 
phosphatase-1 (Wip1, also called PPM1D) (An et al., 2011). Wip1 dephosphorylates p53 
resulting in destabilization and inactivation of p53 (Fiscella et al., 1997), and Wip1 activity 
sensitizes tumors with inactive p53 to anticancer drugs, while at the same time protects normal 
tissues via suppressing wtp53 activation (Goloudina et al., 2011). To determine if Wip1 is 
required for regulation of p53 levels observed upon loss of LZAP, LZAP was depleted by 
lentiviral shRNA in wild-type and Wip1
-/-
 MEFs. The level of p53 was similarly decreased in 
cells with and without Wip1 suggesting that Wip1 was not required for p53 regulation by LZAP 
(Fig. 3.7A). 
 
Although LZAP does not bind HDM2 (Wang et al., 2006), HDM2 is perhaps the most prominent 
regulator of p53 as indicated by its amplification and overexpression in human cancers and by 
p53-mediated embryonic lethality observed upon HDM2 deletion. HDM2 binds p53, inhibits its 
transactivation activity and directly ubiquitinates p53, ultimately leading to its proteasomal 
degradation. To determine if HDM2 is required for downregulation of p53 protein observed  
77 
 
  
Figure 3.6. LZAP Loss Sensitizes Cells Expressing Mutant p53 to Radiation 
Saos-2 cells were co-transfected with siCtrl or siLZAP, and empty vector or p53 mutants 
R175H or R248Q. Clonogenic survival assay was performed after increasing doses of IR. 
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Figure 3.7. p53 Downregulation in LZAP Depleted Cells Does Not Require Mdm2 or 
Wip1 
(A) Immunoblots of LZAP, p53, and Wip1 of lysates derived from wild-type or Wip-1 
knockout MEFs with or without LZAP knockdown.  Immunoblotting of β-actin serves as 
loading control. 
(B) Immunoblots of LZAP, p53, and MDM2 of lysates derived from wild-type or p53/MDM2 
double knockout MEFs transfected with GFP-wtp53 with or without LZAP knockdown.  
Immunoblotting of b-actin serves as loading control. 
(C) Ubiquitination of p53 in U2OS cells with and without LZAP knockdown. p53 ubiquitin 
ladders were detected by p53 immunoprecipitation and p53 immunoblotting following 
proteasomal inhibition. Input levels of p53 and LZAP with and without LZAP knockdown 
are shown (1/20 of input bottom panels). 
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following LZAP loss, LZAP was depleted by siRNA transfection in wild-type MEFs and 
MDM2/p53 double null MEFs engineered to ectopically express GFP-wtp53. In cells lacking 
MDM2, exogenously expressed p53 was efficiently decreased following loss of LZAP (Fig. 
3.7B). HDM2 primarily decreases p53 levels through direct ubiquitination that targets p53 for 
proteasomal degradation. Increased p53 ubiquitination was not observed following proteasomal 
inhibition in U2OS cells transfected with siRNA targeting LZAP compared to control transfected 
cells (Fig. 3.7C). 
 
These data suggest that downregulation of p53 protein observed following depletion of LZAP 
does not require ARF, Wip1, or HDM2. 
  
Depletion of LZAP Downregulates p53 At Multiple Levels 
Given that LZAP regulation of p53 was not dependent on ARF, Wip1, or HDM2, TP53 gene 
transcription, message translation, and protein stability were explored to better define potential 
mechanism(s) of p53 downregulation triggered by depletion of LZAP. p53 is important for 
cellular processes such as cell cycle, differentiation, immune response, metabolism, DNA repair 
and senescence, and is a potent inducer of apoptosis; therefore, p53 protein levels are tightly 
regulated by multiple mechanisms (Hupp et al., 2000; Vogelstein et al., 2000). Since protein 
stability is a major pathway of p53 regulation, the effect of LZAP loss on p53 stability was 
determined using cycloheximide to inhibit protein synthesis. p53 stability was decreased by 
approximately 33% (from 57 to 38 min) after siRNA-mediated LZAP depletion (Fig. 3.8A). Co-
transfection with a construct driving expression of a siRNA-resistant LZAP restored p53 half-life 
confirming that loss of LZAP was responsible for p53 destabilization. Interestingly, HDM2 
protein level was also decreased after LZAP downregulation in MEFs (Fig. 3.7B) and no 
induction of p53 ubiquitination was observed in LZAP-depleted U2OS cells (Fig. 3.7C),  
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  Figure 3.8. LZAP Loss Downregulates p53 Expression at Multiple Levels 
(A) LZAP depletion destabilizes p53. Left: Immunoblot detecting LZAP and p53 in U2OS 
cells with and without LZAP knockdown or in cells with LZAP knockdown and 
expression of si-RNA resistant LZAP construct (sm-LZAP). Cells were treated with 
cycloheximide (CHX) for the indicated times. Right: Relative quantification of p53 
immunoblots normalized to β-actin. 
(B) Proteasomal inhibition only partially restores p53 levels in LZAP depleted cells. 
Immunoblot detecting p53 and LZAP in U2OS cells with and without LZAP knockdown 
in the presence or absence of proteasomal inhibitor (MG132). Relative quantification of 
p53 immunoblots normalized to GAPDH. p53 levels in siRNA control transfected cells 
were assigned a value of 1 and are compared to similar cells (either with or without 
MG132) transfected with LZAP siRNA. 
(C) p53 mRNA levels are modestly decreased after LZAP knockdown. qRT-PCR of LZAP 
and p53 mRNA in U2OS cells infected by shCtrl or shLZAP normalized to β-actin. 
(D) LZAP inhibits p53 translation. Translation of p53 in FaDu (mtp53) and SCC61 (wtp53) 
cells was measured by culturing cells in the present of 
35
[S]-methionine for 10 min before 
lysis. Autoradiography of immunoprecipitated p53 (top panel) in cells with and without 
LZAP knockdown. Autoradiography of whole cell extract (WCE) is a measure of global 
translation (middle panel). Immunoprecipitation and immunoblotting of p53 demonstrates 
total p53 levels in cells with and without LZAP knockdown. 
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suggesting that LZAP regulation of p53 stability is independent of the classic ubiquitin-mediated 
pathway. 
 
The magnitude of p53 downregulation observed following LZAP depletion (up to 70%) and the 
inability of the proteasome inhibitor to completely restore p53 in LZAP depleted cells (Fig. 3.8B) 
suggested that additional mechanism(s) of p53 regulation may be driving LZAP activity toward 
p53. To determine if LZAP loss regulates p53 other than through protein stability, TP53 gene 
transcription and message translation were explored. TP53 mRNA levels were measured by qRT-
PCR with and without LZAP depletion in U2OS cells. LZAP depletion by siRNA resulted in a 
reproducible small (15%), but not significant decrease of p53 mRNA levels (Fig. 3.8C, p > 0.05). 
However, LZAP depletion dramatically decreased p53 protein level even when ectopic promoters 
(CMV) were driving p53 transcription (Fig. 3.1D and 3.7B), indicating that p53 transcription is 
not likely the primary mechanism of p53 regulation by LZAP. To determine if LZAP regulates 
translation of p53 message, cells were metabolically labeled (
35
S-methionine) after LZAP 
depletion. A short metabolic labeling pulse followed by p53 immunoprecipitation and 
autoradiography revealed that p53 translation was decreased by approximately 70% in unstressed 
cells independent of p53 mutation status (FaDu expressing mtp53 and SCC-61 expressing wtp53) 
(Fig. 3.8D). LZAP downregulation did not influence global translation rate as indicated by 
equivalent 
35
S incorporation in whole cell lysates derived from cells with and without LZAP 
knockdown (Fig. 3.8D). 
 
Taken together, these data suggest that loss of LZAP decreases p53 protein stability and slows the 
rate of TP53 message translation. 
 
LZAP Binds NCL and Modulates NCL Protein Levels 
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To discover potential protein mediators of LZAP biological activities, LZAP binding partners 
were identified by mass spectrometry after co-immunoprecipitation using antibodies specific to 
Flag-tagged LZAP. From potential LZAP-binding proteins identified, NCL was further evaluated 
because of its reported p53 regulatory activities. Nineteen peptides covering 30.3% of NCL 
amino acid sequence were identified following LZAP immunoprecipitation (Fig. 3.9), and LZAP 
and NCL binding was confirmed by reciprocal immunoprecipitation of endogenous proteins from 
U2OS cell lysate using antibodies specific to either LZAP or NCL (Fig 3.10A). Specificity of 
LZAP and NCL co-immunoprecipitation was confirmed by immunoprecipitation of identical 
lysates with non-specific IgG before immunoblotting. Interestingly, NCL regulates p53 at 
multiple levels. First, it binds the 5’ UTR of p53 mRNA, and overexpression of NCL suppresses 
p53 translation and induction after DNA damage, whereas NCL downregulation increases p53 
protein expression (Takagi et al., 2005). Second, depletion of NCL increases p53 protein stability 
and activity (Yang et al., 2011). Intriguingly, depletion of LZAP in U2OS cells elevated NCL 
levels even in cells transfected with NCL siRNA (Fig. 3.10B and C). To determine if p53 loss 
observed after LZAP depletion was dependent on upregulation of NCL, LZAP and NCL were 
simultaneously depleted by siRNA transfection. As noted above, loss of LZAP partially 
abrogated the ability of siRNA to deplete NCL; however, incomplete depletion of NCL in LZAP 
knockdown cells partially restored p53 levels (Fig. 3.10C). Moreover, increased NCL protein 
expression observed following downregulation of LZAP inversely correlated with decreased p53 
protein levels in head and neck cancer cells, irrespective of p53 mutation status (FaDu expressing 
mtp53 and SCC-61 expressing wtp53) (Fig. 3.10C). Conversely, overexpression of LZAP 
resulted in substantial decrease in NCL level (Fig. 3.10D). 
 
These data show that LZAP binds to and negatively regulates NCL and that loss of LZAP 
expression increases NCL protein levels. Importantly, these data suggest that NCL is, at least 
partially, responsible for LZAP activity to regulate both mutant and wild-type p53.  
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Figure 3.9. Localization of the peptides identified by mass spectrometry along the NCL 
protein sequence 
The position and length of the peptides are highlighted in gray. 
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  Figure 3.10. LZAP Binds NCL and Negatively Regulates NCL Protein Levels 
(A) Co-immunoprecipitation of LZAP and nucleolin. Immunoblots of endogenous LZAP and 
nucleolin (NCL) after immunoprecipitation with antibodies specific to LZAP or NCL. 
(B) Immunoblot detecting LZAP and nucleolin in U2OS cells with and without LZAP 
knockdown. 
(C) Loss of nucleolin at least partially restores p53 expression in LZAP depleted cells. 
Immunoblots detecting p53 are shown following single knockdown of LZAP or NCL or 
double knockdown of both LZAP and NCL. Immunoblotting of LZAP and nucleolin 
confirm knockdown and GAPDH serves as a loading control. 
(D) Immunoblot detecting LZAP and NCL in U2OS cells ectopically expressing LZAP. 
Immunoblotting of GAPDH serves as loading control. 
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Loss of LZAP Represents a New Mechanism of p53 Inactivation in Head and Neck Cancer 
The p53 protein does not function properly in human cancers, being inactivated directly by 
mutations in the TP53 gene or indirectly by viral proteins. Alternatively, p53 function can be 
inhibited by alterations in genes whose products regulate p53 itself or signaling to or from p53 
(Hupp et al., 2000; Vogelstein et al., 2000; Lane and Lain, 2002). Altered genes in human cancer 
that impact p53 function include, but are not limited to: amplification and overexpression of a 
major negative p53 regulator, HDM2 (Cordon-cardo et al., 1994; Momand et al., 1998); loss of 
expression of p14ARF, a negative regulator of HDM2 (Iida et al., 2000); overexpression of 
ΔNp73 (NH2-terminally truncated, transactivation-deficient dominant-negative isoform of p53 
homologue p73), which blocks p53 activities (Zaika et al., 2002; Romani et al., 2003; Concin, 
2004); mutations in tumor suppressor and phosphatase, PTEN (Mayo et al., 2002); and, 
disruption of Chk1/2 signaling (Shieh et al., 2000). Our data suggest that depletion of LZAP 
downregulates steady state p53 levels independent of Wip1, MDM2, or ARF, and inhibits 
radiation-induced stabilization and activation of wtp53 (Fig. 3.1, 3.2 and 3.7). We previously 
reported that LZAP protein expression is dramatically decreased in approximately 30% of 
HNSCC. Combined, findings presented here and previously led us to hypothesize that loss of 
LZAP may represent a novel mechanism of p53 inactivation in human cancer. To provide support 
for this hypothesis, human HNSCC (n = 29) (Table 2) were examined to determine if decreased 
expression of LZAP correlated with decreased expression of p53 protein. Because HPV is 
recognized to play a role in the pathogenesis of a subset of HNSCCs (e.g. observed in 40-60% 
oropharynx carcinomas) and HPV inhibits p53 via its E6-mediated degradation, all tumor 
samples used in these studies were tested for their HPV status as described (Seaman et al., 2010) 
and shown to be HPV-negative. p53 and LZAP protein levels from immunoblot were quantified 
and compared between 29 primary tumors. Remarkably, LZAP and p53 levels positively 
correlated with one another (R
2
 = 0.4, p < 0.001) (Fig. 3.11A, left). If tumors containing mutant  
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Table 2. Summary of HNSCC patient information. 
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Figure 3.11. LZAP Loss Inactivates p53 in Head and Neck Cancer 
(A) Graph of LZAP and p53 levels determined by immunoblot band intensity normalized to 
GAPDH with best fit (solid line) and 95% confidence (dashed lines) indicated (primary 
HNSSC, n = 29). Spearman rank correlation p = 0.0004715 (R
2
 = 0.4). Exons 4-10 of 
TP53 were sequenced; blue dots = wtp53, red dots = mtp53. 
(B) Top: Representative photomicrographs of LZAP and p53 IHC in human head and neck 
squamous cell carcinomas. Bottom: Quantification of IHC (primary HNSSC, n = 29); 
high LZAP group = strong staining in > 50% of tumors cells, low LZAP group = weak 
LZAP staining and strong staining in < 50% of tumor cells; similarly high p53 group = 
strong staining in > 50% of tumors cells, low p53 group = weak p53 staining and strong 
staining in < 50% of tumor cells The proportions of low and high p53 staining were 
divided based on low and high LZAP staining. p value < 0.001 analyzed by 2×2 
contingency table. 
(C) Bootstrap analyses were performed to determine the optimal cut-point of LZAP (3.96) for 
predicting p53 mutant status. For each Bootstrap replicate, the optimal cut-point of LZAP 
was determined based on the maximum prediction accuracy (true positive and true 
negative) which was calculated by using logistic regression. 
(D) 29 primary head and neck squamous cell carcinomas were divided into two groups based 
on an optimal cut-off: ―low LZAP‖ < 3.96 and ―high LZAP‖ > 3.96. The number of 
cancer samples with wild-type and mutant p53 is indicated. The ―low LZAP‖ group of 
cancers has a lower proportion of mutated p53 than the ―high LZAP‖ group of cancer 
(p<0.03). 
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p53 were excluded from analyses, LZAP and p53 levels were even more highly correlated (R
2
 = 
0.6, p < 0.0001) (Fig. 3.11A, right). These findings were confirmed by IHC staining using 
antibodies specific to LZAP and p53. Only 25% of tumors within ―high LZAP‖ group (strong 
LZAP IHC in more than 50% of tumor cells) expressed low p53 levels, whereas 71% of ―low 
LZAP‖ tumors (less than 50% of cells with strong LZAP staining or weak LZAP staining) had 
low p53 staining intensity (p < 0.001) (Fig. 3.11B). 
 
LZAP loss correlated with decreased p53 expression in HNSCC, but to begin determining if the 
extent of p53 downregulation following LZAP loss is functionally significant, p53 mutation 
status was determined in 29 head and neck tumors for correlation with LZAP levels. If LZAP-
mediated modulation of p53 was functionally significant in tumorigenesis, HNSCCs with low 
LZAP, and corresponding low p53, should have decreased selection pressure to mutate p53. 
Among 29 samples 8 tumors expressed mutant TP53 (Fig. 3.11A, red dots, and Table 2). 
Segregation of HNSCC into ―low LZAP‖ and ―high LZAP‖ based on optimal LZAP level of 3.96 
(Fig. 3.11C), revealed that the incidence of p53 mutations in the low LZAP group was 11% while 
the incidence of p53 mutations in the high LZAP group was 55% (p < 0.03) (Fig. 3.11D). 
 
Together, these data show that LZAP levels correlate with p53 levels in HNSCC. Further, 
HNSCCs with low LZAP expression display decreased selection pressure to mutant p53, 
suggesting the loss of LZAP is biologically significant in this tumor type. 
 
Discussion  
p53 
Previously, we reported that LZAP is lost in about 30% of HNSCC (Wang et al., 2007b). In this 
study, we discovered that downregulation of LZAP decreased basal p53 protein levels and 
abrogated p53 accumulation, phosphorylation and transactivation typically observed following   
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irradiation (Fig. 3.1, 3.2, 3.5 and 3.10). Remarkably, p53 and LZAP protein levels correlated in 
primary HNSCC, and tumors with downregulated LZAP had decreased pressure to inactivate p53 
through mutation (Fig. 3.11). As is typical for many new proteins found to be implicated in 
cancer, the role of LZAP in cancer development and progression is likely to be dependent on 
accompanying molecular defects in the tumor, and the complicated nature of these interactions 
may be beginning to emerge with contradictory reports of LZAP as both an inhibitor of cancer 
cell growth and invasion and a promoter of cell proliferation and metastasis. Given the 
importance of known LZAP-binding partners in human cancer (e.g. ARF, p38, Wip1, RelA, Chk1, 
Chk2) and the dearth of knowledge concerning functional regulation of LZAP through protein-
protein interactions or posttranslational modifications, it is also possible that LZAP may play 
opposing roles in tumor promotion depending on surrounding cellular environment and/or genetic 
defects co-existing in the tumor. Data reported herein further support LZAP as a tumor 
suppressor in HNSCC and suggest that activation of p53 is one of its major functions. Squamous 
cell carcinoma is an epithelial cancer that occurs in organs from different anatomic sites, 
including the skin, lung, esophagus and urogenital tract. Since SCCs from the head and neck and 
some other sites share common characteristics (e.g. risk factors, molecular defects and prognostic 
markers) (Mak et al., 2011), it will be important to determine if LZAP also plays a role in 
inactivation of p53 in these cancers. In addition larger numbers of HNSCC patients should be 
examined to determine if LZAP status correlates with prognosis as has been observed for 
hepatocellular carcinoma (Zhao et al., 2011). 
 
Anticancer Therapies 
One very interesting finding of our studies is that LZAP depletion decreased both wild-type and 
mutant p53 levels (Fig. 3.1 and 3.10) and regulated DNA damage-induced cell death in the p53-
dependent manner. Although a treatment strategy of simultaneous temporal downregulation of 
mutant and wild-type p53 has not been extensively explored, in theory, this strategy should 
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sensitize tumors with mutant p53 to radiation and chemotherapy and at the same time protect 
normal, wtp53 expressing tissues. Support for this potential therapeutic strategy was provided by 
clonogenic survival and proliferation assays revealing that depletion of LZAP in cells with wtp53 
expression increased their resistance to radiation and several DNA damaging drugs (Fig 3.2 and 
3.4). Remarkably, loss of a single lzap allele in mice increased radiation resistance of bone 
marrow progenitors (Fig. 3.5). In contrast, downregulation of LZAP in cells lacking p53 or 
expressing mtp53 sensitized cells to DNA damaging agents (Fig. 3.2, 3.4 and 3.6). We focused 
our study on LZAP activities towards p53, therefore mechanisms of how LZAP depletion alters 
sensitivity of p53 nulls cells to DNA damage-induced cell death remain to be elucidated. Related 
to LZAP activity to p53, it is possible that inability of LZAP depleted cells to arrest in G1 phase 
of cell cycle (Wang et al., 2006; Liu et al., 2011) may increase apoptosis in response to stress 
signals. Recently, it has been discovered that the immediate activation of p53 upon DNA damage 
is responsible for toxic side effects, but is not required for the suppression of carcinogenesis 
(Christophorou et al., 2006). p53 activity is required for prevention of tumors during the period 
following recovery from DNA damage (Junttila and Evan, 2009), suggesting that temporary 
inhibition of p53 in normal cells will not increase tumor formation in patients who survive long 
term. We suggest that transient LZAP depletion or inhibition of LZAP activities toward p53 
immediately before and during DNA damaging anticancer therapy could minimize p53-dependent 
toxicity in normal tissues without decreasing tumor-suppression mediated by p53, which would 
be activated normally once the temporary inhibition of LZAP activity was relieved. 
 
NCL 
Mechanistically, we found that depletion of LZAP downregulated p53 at multiple levels. LZAP 
has no known enzymatic activity, and diminished p53 levels associated with LZAP depletion 
were independent of ARF and WIP1 – known LZAP binding proteins, controlling p53, and also 
independent of MDM2 – a major p53-negative regulator (Fig. 3.7). Interestingly, our data also 
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suggest that following LZAP depletion, p53 protein was destabilized independent of 
ubiquitination of p53 (Fig. 3.7C). To identify potential mediators of LZAP activity toward p53, 
we used mass spectroscopy to determine potential LZAP binding partners. NCL was found and 
confirmed as an LZAP-associated protein (Fig. 3.9 and 3.10A). Excitingly, we discovered that 
LZAP regulated NCL protein expression, with depletion of LZAP leading to increased NCL and 
overexpression of LZAP resulting in decreased NCL protein levels (Fig. 3.10). Further, increased 
NCL levels observed following LZAP depletion correlated well with decreased p53 protein levels 
irrespective of p53 mutation status (Fig. 3.10C). These findings are consistent with a described 
role of NCL as an inhibitor of p53 through decreasing p53 half-life and inhibiting p53 translation. 
 
Elevated expression of NCL has been associated with pathological conditions, including cancer, 
autoimmunity, viral infection and neurodegenerative processes (Dranovsky et al., 2001; Ugrinova 
et al., 2007; Callé et al., 2008; Caudle et al., 2009). Despite these links to human disease, little is 
known about regulation of NCL. The extracellular-regulated kinase (Erk) increases NCL RNA 
expression and protein half-life in peripheral blood mononuclear cells (Westmark and Malter, 
2001), and the RNA binding protein HuR promotes NCL translation, while miR-494 lowers NCL 
expression by competing with HuR (Tominaga et al., 2011). NCL has been associated with 
inhibition of HDM2 and p53 stabilization (Saxena et al., 2006), but other studies show that NCL 
inhibits p53 through both protein destabilization and inhibition of p53 translation (Takagi et al., 
2005; Yang et al., 2011). Our data support an inhibitory role of NCL toward p53 specifically after 
NCL levels were increased following LZAP loss. Although further detailed studies are needed to 
clarify molecular mechanism(s) and specificity of NCL regulation by LZAP, our data suggest that 
NCL upregulation following LZAP depletion alters cells sensitivity to DNA damage (e.g. 
radiation and chemotherapeutic drugs treatment) in a p53-dependent manner. 
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In summary, these studies have identified a new mechanism of p53 inactivation in human cancer, 
linking LZAP loss with downregulation of p53 in HNSCC. Remarkably, the pressure to mutate 
p53 was diminished in HNSCC with low LZAP levels. These data further support LZAP as a 
tumor suppressor and suggest that loss of LZAP can mitigate p53 activity in tumorigenesis. In the 
presence of LZAP loss, p53 downregulation was at least partially dependent on LZAP regulation 
of NCL. LZAP depletion was found to protect normal and tumor cells expressing wtp53 from 
genotoxic stress, while sensitizing cells without p53 expression or expressing mutant p53 (Fig. 
3.12). These findings raise important therapeutic considerations and suggest that strategies or 
drugs that temporarily inhibit LZAP activity toward p53 may be useful for treating p53 mutant or 
null cancers while simultaneously protecting normal tissues from DNA damaging therapeutic 
agents. 
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  Figure 3.12. Proposed Working Model 
Schematic summarizing findings that LZAP loss inactivates p53 in human cancer and 
modulates cells sensitivity to DNA damage in a p53-dependent manner. 
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CHAPTER IV 
 
CONCLUSION AND DISCUSSION 
 
Conclusion 
LZAP activities are important in development and in tumorigenesis. Understand the biological 
significance of LZAP and discerning its mechanisms will provide novel insight into normal 
cellular biology and cancer cell biology. Studies here describe LZAP as a critical regulator of 
early embryogenesis in zebrafish and mice, and describe LZAP loss as a novel mechanism to 
decrease p53 activity in human cancer. A clearer understanding of LZAP mechanisms of action 
and its tumor suppressing function is biologically significant, as results presented here describe a 
clear opportunity for development of therapeutic strategies for human tumors with LZAP loss or 
with mutant or null p53. 
 
We discovered LZAP as a novel ARF-binding partner and described LZAP as an activator of p53, 
both dependent and independent of ARF. Thus, LZAP’s tumor suppressor activity is driven by 
oncogenic stimulation increasing LZAP binding to ARF resulting in p53 activation. We also 
described that LZAP binds RelA (NF-κB), decreases RelA phosphorylation, inhibits NF-κB 
transcription, and increases RelA association with HDACs, likely resulting in an inhibitory NF-
κB complex on chromatin. Loss of LZAP accelerates tumor cell invasion, as well as xenograft 
tumor growth and angiogenesis, and is associated with increased expression of select NF-κB 
targets. Other groups have shown that LZAP accelerates cell death in response to 
chemotherapeutic agents and alters the G2/M cell cycle checkpoint through inhibition of Chk1 
and Chk2. The potential tumor suppressor activities of LZAP have continued to emerge with our 
description that LZAP expression is lost in 30% of human HNSCC. Human tumor and xenograft 
mouse tumor data, as well as, LZAP activities as an activator of the p53 pathway and suppressor 
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of NF-κB activity suggest that LZAP likely functions as a tumor suppressor; however, validation 
of LZAP tumor suppressor status has been lacking. Recently, we have found and confirmed that 
LZAP binds the stress activated protein kinase, p38 MAPK. LZAP inhibits p38 phosphorylation 
and kinase activity, and this LZAP activity is at least partially dependent on the oncogenic 
phosphatase Wip1. Our preliminary and reported data suggest that LZAP binds Wip1, but 
variably regulates Wip1 activity toward its substrates possibly dependent on LZAP’s ability to 
bind the substrate, as discussed in the introduction chapter (Table 1). Because LZAP has no 
conserved enzymatic domains and no known enzymatic activity, potential mediators of LZAP 
activities were sought by co-immunoprecipitation. We found several potential LZAP-associated 
proteins including NCL which was explored in this thesis. The number of cancer-centric proteins 
that LZAP regulates through direct or indirect interactions is remarkable, as we propose in the 
LZAP network (Fig. 4.1). Interestingly, the majority of LZAP regulated proteins have activities 
towards p53. Chk1, Chk2 and p38MAPK phosphorylate and activate p53 directly in response to 
DNA damage, whereas MDM2 and Wip1 are negative regulators of p53. Overexpression of the 
LZAP-associated protein NCL can suppress p53 translation and destabilize p53 (Fig. 4.1). These 
findings suggest that the tumor suppressor functions of LZAP can be largely attributed to 
regulation of p53 tumor suppressor. 
 
To further explore putative tumor suppressor activities of LZAP, we targeted LZAP in mice. 
However, homozygous LZAP (LZAP
-/-
) knockout in mice resulted in early embryonic lethality, 
before embryonic day 4.5, which led us to explore developmental defects resulting from LZAP 
loss. Mice are not the idea model to study the critical functions of LZAP in early embryogenesis, 
thus, we explored developmental consequences of LZAP loss using zebrafish, which provide an 
opportunity to examine the earliest cell behaviors in live embryos. LZAP loss using MO in 
zebrafish results in early embryonic lethality reminiscent of lethality observed in mice. LZAP is  
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Figure 4.1. Proposed LZAP Network 
Schematic summary of LZAP regulated cancer-centric proteins. Proteins are represented by 
ovals. Solid lines show direct interactions and dashed lines indicate indirect interactions. 
Green lines represent activating interactions, red lines represent inhibitory interactions, and 
black arrows represent interactions that can be either inhibitory or activating. 
97 
 
highly conserved at the amino acid level among vertebrates and is maternally deposited. 
Expression in zebrafish is initially ubiquitous during gastrulation, but later becomes more 
prominent in the pharyngeal arches, aero-digestive tract, and brain. Antisense MO-mediated 
depletion of LZAP results in delayed cell divisions and apoptosis during blastomere formation, 
with resultant fewer, larger cells. Cell cycle analysis in early lzap morphant embryonic cells 
reveals that LZAP loss results in delayed exit from G2/M. Furthermore, LZAP-deﬁcient embryos 
fail to initiate epiboly—the earliest morphogenetic movement in animal development—which has 
been shown to be dependent on cell adhesion. Our results strongly implicate LZAP in regulation 
of cell cycle progression, cell viability and potentially cell adhesion during early development. 
LZAP also appears to be required for initiation of epiboly. Inhibition of doming and epiboly in 
lzap morphants is exciting and suggest that LZAP activity is required at or before the earliest 
stages of cellular and tissue differentiation. Loss of LZAP disrupts development at a stage where 
embryonic cells should maintain a pluripotency, suggesting that LZAP is required for embryonic 
stem cell maintenance or appropriate cell fate determination. 
 
Here, we also present data supporting a role of LZAP loss as a novel mechanism of inactivation 
of p53 in human tumors. Downregulation of p53 protein levels and activity following LZAP 
depletion was observed even after cell exposure to IR. Mechanistically, we found that LZAP 
regulates p53 at multiple levels (protein translation and protein stability). Since LZAP has no 
obvious enzymatic domains, LZAP activities described to date are mediated through LZAP 
associated proteins. To discover potential mediators of ARF-independent LZAP activity toward 
p53, LZAP binding partners were identified using affinity precipitation and mass spectroscopy. 
Among others, we identified NCL as an LZAP-associated protein and confirmed endogenous 
binding between LZAP and NCL in mammalian cells. Excitingly, we discovered that depletion of 
LZAP resulted in markedly increased NCL protein levels. NCL is an established negative 
regulator of p53 through both protein destabilization and inhibition of p53 translation. Supporting 
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a putative role of LZAP as a regulator of p53, we found that low levels of LZAP correlated with 
decreased p53 protein levels in primary HNSCC. If loss of LZAP indeed represents a new 
pathway of p53 inactivation in human cancer, tumors with downregulated LZAP would be 
expected to have decreased pressure to mutate p53. Among primary HNSCCs screened, we found 
that tumors with ―low LZAP‖ had significantly fewer p53 mutations compared to ―high LZAP‖ 
specimens. Remarkably, loss of LZAP dramatically reduced both wtp53 and mtp53 protein levels. 
Mutations of the p53 gene are found in approximately 50% of human tumors and are associated 
with poor prognosis in many tumors, including HNSCC. Many p53 mutations convey gain-of-
function activity that increases resistance to DNA damaging therapy suggesting that inhibition of 
mutant p53 is a therapeutic strategy to enhance response to conventional chemotherapeutic drugs 
or radiation. On the other hand, wtp53 activity, while important for prevention of tumor 
development, is also a driver of injury to non-cancer cells following anticancer therapy. Therefore, 
transient downregulation or suppression of wtp53 function has long been proposed and 
experimentally tested as a strategy to protect normal cells during radiation or chemotherapy. Our 
preliminary data indicate that LZAP loss regulated cell survival after DNA damage dependent on 
p53-status, with wtp53 cells being protected while mtp53 or null cells were sensitized. This effect 
was independent of ARF expression. Together, these findings suggest that temporary inhibition of 
LZAP activity toward p53 could be useful for therapy of p53 mutant tumors by simultaneously 
sensitizing the tumor to DNA damaging agents (chemotherapy or radiation) while protecting 
normal surrounding tissue (Fig. 3.12). 
 
Discussion 
Our work to study LZAP activity has increased our understanding, but also left many new and 
exciting areas for future exploration. The diverse roles of LZAP in human cancer and 
development are only beginning to be explored. Since we have been at the forefront of the LZAP 
field, we are privileged to speculate about these roles. Here is a partial list of many possibilities. 
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Does LZAP regulate Wip1 activities, or does Wip1 mediate LZAP activities, or both? 
LZAP alters activity of a variety of proteins (p53, Chk1/2, p38, RelA, etc.) which have been 
implicated of great importance in tumorigenesis (Wang et al., 2006; Jiang et al., 2009; An et al., 
2011), and interestingly, these LZAP regulated proteins are also substrates of the Wip1 
phosphatase (Takekawa et al., 2000; Fujimoto et al., 2006; Chew et al., 2009). In one of our 
publications, we found that Wip1 is required for LZAP regulation on p38MAPK and that LZAP 
increases Wip1 binding to p38 (An et al., 2011), suggesting that Wip1 may also be the mediator 
of LZAP activity toward proteins whose activity is commonly targeted by both Wip1 and LZAP. 
Unlike LZAP, which is a putative tumor suppressor, the Wip1 phosphatase has been primarily 
considered as an oncogenic protein, primarily due to its negative regulation of ARF and p53. In 
contrast to its dominant oncogenic activities, Wip1 has also been found to dephosphorylate and 
inhibit oncogenic properties of NF-κB (RelA) signaling, suggesting that Wip1 could also have 
tumor suppressive. To date, no protein regulators of Wip1 activity or substrate specificity have 
been described. In table 1, we summarized the common targets of LZAP and Wip1, but we 
noticed that LZAP directly binds to portion of those. Remarkably, if LZAP binds to Wip1 
substrates LZAP and Wip1 have parallel effects on substrate activity; however, if LZAP does not 
bind to the Wip1 substrate, as is the case for p53 and MDM2, LZAP effect on substrate activity is 
opposite that of Wip1. Therefore, we hypothesize that LZAP regulation of Wip1 activity depends 
on LZAP ability to bind those substrates. It is possible that LZAP regulation of Wip1 may reduce 
much of Wip1 oncogenic activities (e.g. inhibition of p53) while increasing its tumor suppressor 
activities (e.g. inhibition of RelA). 
 
Our data, particularly findings related to p38, suggest that LZAP may require Wip1 to mediate its 
effects toward proteins that both LZAP and Wip1 target (e.g. Chk1/2, RelA). Our preliminary 
data suggest that LZAP and Wip1 bind one another in vivo and in vitro (data not shown), but the 
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exact binding domains of each protein remain to be characterized. LZAP truncation mutants will 
be used to narrow region(s) of LZAP required for Wip1 binding and conserved amino acids 
within LZAP mutated in attempts to generate LZAP point mutants unable to bind Wip1. LZAP 
exists as a dimer or polymer (data not shown and Jiang et al., 2009) and polymerization of LZAP 
may be required for binding to Wip1, which could complicate mapping experiments. Similarly, 
identification of Wip1 mutants that cannot bind LZAP, but that maintain binding and activity 
toward Wip1 substrates will be useful to determine the role of LZAP in regulating Wip1 activity. 
 
We believe that creation of LZAP and Wip1 mutant that cannot bind to one another will greatly 
enhance understanding of the functional relationship between LZAP and Wip1. 
 
LZAP has no reported enzymatic domains or activities, but we and others discovered that it 
regulates the activities of many associated protein by dephosphorylating them at serine residues. 
It remains unclear if Wip1 is the only or major mediator of these LZAP activities. Future 
experiments can determine the role of Wip1 in LZAP-mediated inhibition of RelA and Chk1/2, 
and LZAP-mediated activation of p53? Based on this work, we may find more potential LZAP 
regulated proteins and mechanistically explain LZAP activity as a tumor suppressor. 
 
Ultimately we will identify the extent to which Wip1 and LZAP co-regulate one another to 
promote or inhibit activities important in tumorigenesis. 
 
Does downregulation of LZAP protect organisms from IR?  
IR-induced death in mammals is primary due to the induction of apoptosis in radiosensitive 
organs resulting in two well-described acute radiation syndromes, hematopoietic (HP) syndrome 
and gastrointestinal tract (GI) syndrome, that result in dose-dependent organismal damage or 
death (Gudkov and Komarova, 2003). Several lines of evidence reveal that p53 is a major 
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determinant of IR-induced cell death. First, p53 knockout mice are resistant to IR doses (8-10 Gy) 
that induce HP syndrome resulting in severe morbidity or mortality (Gudkov and Komarova, 
2005). Second, temporary pharmacological inhibition of p53 protects wtp53 expressing cells from 
radiation and improves survival of wild-type mice through prevention of HP syndrome (Komarov 
et al., 1999; Strom et al., 2006). p53-induced apoptosis during radiation and chemotherapy is a 
major cause of severe side effects during the treatment (Botchkarev et al., 2000; Strom et al., 
2006), therefore transient downregulation or suppression of p53 function has been suggested as a 
therapeutic strategy to protect normal cells, and therefore tissues during treatment. However, p53 
knockout mice, although being resistant to HP syndrome, at the same time are more sensitive to 
the higher IR doses (12-20 Gy) that induce GI syndrome, indicating that p53 plays a dual role in 
response to radiation, inducing apoptosis in hematopoietic tissues, but protecting GI tract cells 
from cell death at higher radiation doses (Komarova et al., 2004; Kirsch et al., 2010). The 
mechanisms underlying the protective role of p53 in GI tract is not completely understood, but 
may be explained the ability of p53 to induce cell cycle arrest or senescence in response to high 
doses of IR, whereas p53-null cells continue to proliferate leading to mitotic catastrophe and 
death from unrepaired DNA damage (Gudkov and Komarova, 2003; Komarova et al., 2004). 
 
Our preliminary data suggest that ES cells derived from LZAP
+/-
 mice expressed lower levels of 
p53 compared to LZAP
+/+
 mice (Fig. 3.1A). Loss of one allele of lzap in mice protected bone 
marrow cells from IR (Fig. 3.5). Remarkably, even after stimulation with radiation, increases in 
p53 levels and activity was attenuated in bone marrow cells from LZAP
+/-
 mice (Fig. 3.5). Given 
that p53 is a major driver of apoptosis in bone marrow following IR, we suspected and confirmed 
that loss of one lzap allele in mice protected bone marrow cells from moderate dose of IR (8-10 
Gy), suggesting that depletion of LZAP with resultant downregulation of p53 renders cells more 
resistant to IR. 
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Several intriguing questions concerning the role of LZAP loss in transgenic mice exist. Because 
LZAP
-/-
 homozygous knockout mice are not available due to early embryonic lethality, LZAP
+/-
 
heterozygous mice, which have been shown to express less LZAP protein in tissues compared to 
their wild-type siblings, will be used in future experiments. Questions that can be explored 
include: Will LZAP
+/-
 mice be protected from HP syndrome? And if so, because p53 deficient 
mice are extremely susceptible to IR-induced carcinogenesis, will mice that survive after 
radiation have increased or altered tumor incidence, latency or spectrum? Will LZAP
+/-
 mice be 
sensitized to the IR-induced GI syndrome, as was observed in p53 deficient mice? 
 
Our preliminary results demonstrate that depletion of LZAP in wtp53 cells increased cellular 
resistance to DNA damaging agents, but has the opposite effect in p53 null and mtp53 cells (Fig 
3.2 and 3.4). Given these results it would be interesting to explore if the sensitizing effects of 
LZAP depletion also occurs in vivo. HCT116 p53
+/+
 and p53
-/-
 cell lines can be manipulated for 
mutant p53 expression and LZAP depletion with controls, and then inoculated into NUDE mice 
in a xenograft model. Addressing and beginning to understand these questions will provide a 
much deeper understanding of the role of LZAP downregulation in regulation of cellular 
sensitivity to IR in vivo with potential approaches that could impact clinical cancer care. 
 
What are the molecular mechanisms by which LZAP regulates NCL? 
Our preliminary data suggest that depletion of LZAP downregulated p53 at multiple levels, 
including minimally at the mRNA level, and primarily through increasing p53 translation and 
protein stability. LZAP effects on p53 occurred regardless of p53 wild-type or mutant status. 
Interestingly, the proteasome inhibitor MG132, failed to completely restore p53 levels in LZAP 
depleted cells and LZAP depletion resulted in efficient downregulation of p53 in both MDM2 
knockout and wild type MEFs (Fig. 3.7). These data suggest that the classic ubiquitin-proteasome 
regulation of p53 was not totally responsible for LZAP activity. Neither exogenous nor 
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endogenous LZAP/p53 complexes were detected in human cells (Wang et al., 2006). Here we 
showed LZAP bound NCL and depletion of LZAP was associated with upregulation of NCL 
levels, which correlated well with downregulation of p53 (Fig. 3.10). Although NCL is 
upregulated in cancer, autoimmune syndromes, Alzheimer’s and Parkinson’s diseases and other 
pathological conditions (Caudle et al., 2009), very little is known about regulation of its levels 
and activities. As such, LZAP may be the first protein regulator of NCL. Therefore, discovery of 
mechanisms through which LZAP regulates NCL may have broader implications for cancer and 
other human disease. 
 
The effect of LZAP to alter NCL protein levels will be tested initially by determining NCL 
stability by using cycloheximide treatment and metabolic labeling with 
35
S methionine. In 
addition, because the half-life/stability of NCL and its regulation are not well described, we 
cannot rule out the possibility that LZAP may affect NCL mRNA expression and/or mRNA 
stability. Therefore, we determine NCL mRNA levels by qRT-PCR following manipulation of 
LZAP levels.  
 
NCL is an extraordinary multifunctional protein that is found in multiple cell compartments, 
including nucleoli, nucleoplasm, cytoplasm and cell surface, with the described roles in 
transcription and translation, chromatin remodeling and viral infection (Mongelard and Bouvet, 
2007; Tajrishi et al., 2011). Detailed molecular mechanisms of many NCL functions are not fully 
characterized, but subcellular localization of NCL may partially reflect and explain its 
involvement in different cellular processes. Since a number of stress stimuli have been shown to 
induce changes in the cellular localization of NCL and since LZAP was in the complex associated 
with NCL, we are interested in determining whether LZAP alters NCL subcellular localization. 
Questions that can be addressed include: Do LZAP and NCL co-localize in cells? Does LZAP 
alter NCL localization or vice versa? Does LZAP alter NCL levels in different compartments? 
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Does LZAP alter NCL association with other binding partners? Our lab has previously shown that 
ectopic expressed LZAP primarily localizes to both cytoplasm and nucleus with exclusion from 
the nucleolus in many cell types, thus there are overlapping compartments for their possible co-
localization (Wang et al., 2006). 
 
If we are successful in creating point/deletion mutants of LZAP that are incapable of binding to 
NCL we will be able to determine to what degree NCL mediates LZAP effects. In particular, we 
will determine if LZAP mutants incapable of binding NCL will retain ability to regulate p53 
levels and activities, and abilities to regulate RelA, p38, Chk1/2 phosphorylation and activity. We 
also will create a series of NCL mutants and test their LZAP dependency. Identification of LZAP 
and NCL regions that are important for binding and regulation of activity will create a scientific 
basis for the future rational design of small molecules that could inhibit LZAP/NCL complex 
formation and potentially mimic LZAP loss with inhibition of p53. 
 
However, it may be impossible to generate mutants of LZAP (or NCL) that are unable to bind 
NCL (or LZAP) because of the complicated or extended protein-protein interaction domains or 
3D structures. How then can we determine if LZAP depends on NCL given that neither NCL 
knockout nor transgenic mice have been reported, and no mammalian cell line exists with loss of 
or inactivating mutations of NCL. Fortunately, we can take an advantage of chicken B 
lymphocyte (DT40) cells with conditional knockout of NCL (Storck et al., 2009). These cells do 
not express NCL after 4-hydroxytamoxifen-induced MerCreMer recombinase activity. Once NCL 
is knocked out, effects of LZAP can be determined. 
 
Here we reported that downregulation of LZAP dramatically increased NCL levels, suggesting 
that LZAP may be the first protein regulator of NCL. NCL levels, after LZAP knockdown, 
correlated well, but inversely, with decreased p53 protein levels (Fig. 3.10); however, the exact 
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mechanisms detailing how LZAP regulates NCL and p53 levels deserves further characterization. 
NCL binds to the 5’ UTR of p53 mRNA and negatively regulates translation of p53 message. Do 
increased NCL protein levels, as observed following LZAP loss, result in more efficient binding 
of NCL to the 5’ UTR of p53 mRNA? More studies to investigate the molecular mechanisms 
underlying LZAP regulation of NCL and how this alters p53 levels and signaling will aid the 
more comprehensively understanding LZAP and NCL effects in cancer and other pathological 
processes. 
 
Is LZAP loss a more general theme for p53 pathway inactivation in diverse human carcinomas? 
The p53 protein does not function properly in human cancers being inactivated directly by 
mutations in the TP53 gene or by viral proteins, or indirectly through alterations of genes/proteins 
which tightly regulate the p53 pathway (Lane, 1998; Hupp et al., 2000; Vogelstein et al., 2000). 
Our results show that depletion of LZAP downregulated both basal and stimulated p53 levels, and 
prevented IR-induced p53 stabilization and transcriptional activity (Fig. 3.3). Interestingly, 
reduced p53 levels in LZAP depleted cells did not depend on ARF, HDM2 or Wip1 (Fig. 3.7). 
Importantly, we previously reported that LZAP protein expression is lost in approximately 30% 
of HNSCC (Wang et al., 2007b). Therefore, we hypothesized that loss of LZAP might represent a 
novel, undescribed pathway to inactivate p53 in human cancer. This hypothesis is supported by 
data derived from human HNSCC (n = 29) where we demonstrated that LZAP and p53 protein 
levels correlated. In addition, HNSCCs with low expression of LZAP protein had decreased 
pressure to inactivate p53 through mutation or loss. 
 
Squamous cell carcinoma (SCC) is an epithelial cancer that occurs in organs from different 
anatomic sites, including the skin, lungs, esophagus, urinary tract, and cervix. Lung cancer is the 
leading cause of cancer death in the United States, and approximately 30% of all lung cancers are 
SCC. Considering that LZAP is downregulated in about 30% of HNSCC and the fact that SCCs 
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from head and neck and lung show several similarities (e.g. risk factors, molecular characteristics 
and prognostic markers) (Yan et al., 2011), we are particularly interested to determine if LZAP is 
also downregulated in lung SCC. Our studies of zebrafish and mouse tissues revealed that LZAP 
is highly expressed in the gill primordia (in fish) and in lung (in mice); therefore, we are 
interested to determine if LZAP plays a role in inactivation of p53 in the other major lung cancer 
histology, adenocarcinoma. Since p53 and LZAP levels correlated by IHC of HNSCC, lung 
esophageal and other SCC TMAs can be similarly analyzed. After determining if LZAP is lost or 
downregulated in SCCs from distinct organs, p53 mutations status will be correlated with LZAP 
expression levels as was done for HNSCC. Such expanded and multi-site TMA studies can help 
us to determine the spectra of tumors in which LZAP is lost. These studies will identify which 
tumors may benefit if strategies or drugs that temporarily inhibit LZAP activities toward NCL 
and/or p53 are developed. 
 
What are the mediator(s) of LZAP activity in p53 null cells? 
LZAP depletion renders wtp53 cells more resistant to radiation and DNA damaging drugs, but 
remarkably LZAP depletion also sensitizes p53 null cells to radio/chemotherapy-induced cell 
death (Fig. 3.2 and 3.4). These effects are clearly p53-independent because if all LZAP activities 
in response to DNA damage are mediated by p53, there should not be any obvious difference 
between p53 null control cells and p53 null LZAP depleted cells. Unlike other tumor suppressors, 
p53 is rarely deleted or truncated in human cancers. Based on the strong p53-dependent effect of 
LZAP depletion on DNA damage-induced survival, p53-independent effects of LZAP loss may 
be less critical for LZAP activity. However, we think it is still important and may help us to 
understand the full spectrum of LZAP activity. We discovered that depletion of LZAP resulted in 
remarkable downregulation of p21
cip1/waf1
 not only in HCT116 p53
+/+
 cells, but also in HCT116 
p53
-/-
 cells and p53 null Saos-2 cells (data not shown). The cyclin-dependent kinase inhibitor, p21, 
is a well-known p53 target gene, with a major role in promoting cell cycle arrest in response to 
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many stimuli (Abbas and Dutta, 2009). Unlike p53 knockout mice, p21 knockout mice are not 
prone to cancer, suggesting that p53 does not exert its tumor suppressor functions through p21. 
p21 prevents cell proliferation primarily through inhibiting cyclin/Cdk complexes formation that 
is required from cell cycle progression. Moreover, loss of p21 has been shown to increase 
sensitivity to IR, and suppress the development of spontaneous lymphomas (Wang et al., 1997). 
Therefore, p21 and p21-induced G1 cell cycle arrest are considered to have a protective role 
following IR-induced DNA damage. Why and how LZAP regulates p21 levels is unclear, but 
downregulation of p21 in p53
 
null cells upon LZAP depletion could be one mechanism 
responsible for sensitization of p53 null cells to radiation following LZAP depletion. 
 
Concluding Remarks 
Data presented in this thesis suggest that LZAP is critical for early embryogenesis in zebrafish 
and mice, and that loss of LZAP is a driver of HNSCC tumorigenesis. This thesis has focused on 
discovery of mechanisms and biological effects of LZAP in vertebrate development, and on 
LZAP’s function in regulating cancer and normal cell behavior especially sensitivity to DNA 
damage. We discovered LZAP is critical for normal exit of G2/M of the cell cycle and to prevent 
apoptosis in early embryos, which may at least partially explain the absence of LZAP
-/-
 mice born 
following crossing LZAP
+/-
 mice and early embryonic lethality observed in zebrafish following 
MO depletion. LZAP morphants were unable to survive long enough to initiate the earliest stages 
of cell movement and differentiation (doming and epiboly). Together these findings suggest that 
LZAP may be a critical regulator of embryonic stem cell functions such as self-renewal and/or 
differentiation. 
 
Radiation and DNA damaging chemo-therapies are extensively used as clinical anti-cancer 
strategies, but their efficacy is limited by toxicity to non-cancer tissues that are at least partially 
attributed to p53-induced apoptosis in normal cells. Thus, transient downregulation or 
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suppression of p53 activity has been suggested as a therapeutic strategy to protect normal cells 
from side effects during anticancer treatment. Mutations in the TP53 gene occur in approximately 
half of human tumors and these mutations are associated with aggressive tumor behaviors 
including resistance to anticancer therapy. Since normal cells do not carry p53 mutations, 
targeting of mtp53 is a promising anticancer strategy. Although much effort has been expended to 
restore p53 function to mutant p53 tumors with some success, combined strategy of simultaneous 
downregulation of both mtp53 in cancerous tissues and wtp53 in normal surrounding tissues has 
not been extensively addressed, potentially because of lack of a feasible target. Because inhibition 
of LZAP decreases both wild-type and mutant p53 levels, LZAP may be an ideal target for 
treating p53 mutant tumors. Our preliminary data suggest that p53 downregulation in LZAP-
depleted cells is at least partially due to NCL and that LZAP binds to NCL; therefore, targeting of 
the LZAP-NCL interaction may be more specific than generalize targeting of LZAP. 
 
Finally, we tested our hypothesis that p53 is inactivated through loss of LZAP in HNSCC, and 
that cancer cells with downregulated LZAP have reduced pressure to inactivate p53 via mutation. 
The p53 pathway is inactivated in almost all cancer types. Our work presented here defined 
LZAP loss as a novel mechanism of p53 inactivation in human cancers. This work will impact 
several areas of cancer research in both the relatively new LZAP field and the persistently 
important p53 field. 
 
The results reported herein significantly enhance understanding the role of LZAP in development 
and tumorigenesis. It is noteworthy that our proposed model begins to provide some structure to 
understand the diverse functions of LZAP and its other regulated proteins. The p53 LZAP axis 
seems to be a major driver of LZAP activity and may overshadow other activities, especially in 
cells with wtp53. Further development and characterization of the detailed mechanisms of how 
LZAP regulates p53 and NCL will provide further insight into the LZAP activities, as well as the 
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regulation of p53 pathway, and thus would likely have a broad experimental impact. Owing to the 
complexity of LZAP interaction with its various binding proteins and the complicated genetic 
landscape of cancers, additional studies applying our findings to more tumor models and other 
cancer types such as primary non-small cell lung cancer will help to determine appropriate tumors 
that will benefit from LZAP inhibitory strategies. 
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